



**Vaccines and Global Health: The Week in Review
06 January 2024 :: Issue 732
Center for Vaccine Ethics & Policy (CVEP)**

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director

Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

:: [Think Tanks](#)

Editor's Note:

Vaccine and Global Health: The Week in Review resumes publication with this edition of 06 January 2024 following an end-of-year break.

Milestones, Perspectives



Delivering life-saving vaccines to every child in the Gaza Strip

Nearly three months into the escalation of hostilities, an estimated 16,854 children have missed their routine vaccinations, leaving their immunity compromised at a time of significant vulnerability.
UNICEF 31 December 2023

In the Gaza Strip, where about 1.9 million people are internally displaced, life-threatening hostilities continue, and humanitarian space is rapidly shrinking, another, less visible crisis threatens the health and well-being of children.

Nearly three months into the escalation of hostilities, an estimated 16,854 children have missed their routine vaccinations, leaving their immunity compromised at a time of significant vulnerability.

Before October 7, significant progress had been made to improve the health and wellbeing of children in the State of Palestine, with immunization coverage of key vaccines as high as 99 per cent. Despite efforts to maintain immunization coverage since then, the relentless socio-economic decline, ongoing escalations, and interruptions in healthcare services posed significant challenges. The conflict disrupted routine vaccinations and disease surveillance systems in recent weeks, increasing the risk of outbreaks of deadly but preventable diseases, such as measles and polio...

...UNICEF and partners have launched a rapid response to deliver some 962,550 doses of key vaccines, protecting against diseases like measles, pneumonia, and polio. Between 25 December and 29 December, over 600,000 doses of vaccines reached to the Gaza Strip, providing a crucial lifeline for children...

UNICEF is working closely with UNRWA, WHO, NGOs, local partners and other humanitarian actors operating in the Gaza Strip to ensure that all children due for vaccination receive vaccine doses.

UNICEF will support partners to design strategies for reaching these missed children through active tracking and community outreach to encourage caregivers to bring these children to be vaccinated as well as supporting with the organization of vaccination campaigns...



COVID-19 vaccinations shift to regular immunisation as COVAX draws to a close

Joint statement by CEPI, Gavi, UNICEF and World Health Organization (WHO)

- COVAX will close 31 December 2023 having delivered nearly 2 billion doses of vaccines to 146 economies, and averted an estimated 2.7 million deaths in AMC lower-income participating economies.
- COVAX's end-to-end efforts helped lower-income economies achieve two-dose coverage of 57 per cent, compared to the global average of 67 per cent

- Low- and lower middle-income economies will continue to receive COVID-19 vaccines and delivery support from Gavi, the Vaccine Alliance in 2024 and 2025, with 83 million doses so far requested for 2024 from 58 economies.

Geneva/Oslo/New York, 19 December 2023 – COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020, will draw to a close on 31 December. Jointly led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance (Gavi), UNICEF and the World Health Organization (WHO), **COVAX has so far supplied nearly 2 billion COVID-19 vaccine doses and safe injection devices to 146 economies.** Its efforts are estimated to have helped avert the deaths of at least 2.7 million people in the COVAX Advance Market Commitment (AMC) low- and lower middle-income participating economies (lower-income economies) that received free doses through the mechanism, alongside nearly US\$ 2 billion in critical support to turn vaccines into vaccinations.

These 92 lower-income economies that were eligible to participate in the programme with support from the financing mechanism known as the Gavi COVAX Advance Market Commitment (COVAX AMC) **will continue to have the option to receive COVID-19 vaccine doses and delivery support through Gavi's regular programmes. So far, 58 lower-income economies have requested a total of 83 million doses in 2024,** with plans to focus on the continued protection of priority groups, including health care workers, community workers and older adults.

...By the end of 2020, 190 economies of all income levels had signed agreements to participate in COVAX, making it one of the most significant multilateral partnerships of the 21st century. By November 2020, it had raised US\$ 2 billion towards vaccine procurement; and in January 2021, 39 days after the first vaccine administration in a high-income country, the first COVAX-supplied doses were administered in a lower-income country.

COVAX was designed as an end-to-end coordination mechanism encompassing R&D and manufacturing, policy guidance, vaccine portfolio development, regulatory systems, supply allocation and country readiness assessments, transport logistics, vaccine storage and administration, and monitoring country coverage and absorption rates. **However, as an emergency solution launched in the midst of the pandemic, COVAX faced many challenges.** Without having any cash reserves up front, it was initially limited in its ability to sign early contracts with manufacturers, and while it was able to ship doses to 100 economies in the first six weeks of global roll-out, export bans and other factors meant that large-volume deliveries were only received in the third quarter of 2021.

While COVAX was unable to completely overcome the tragic vaccine inequity that characterised the global response, it made a significant contribution to alleviating the suffering caused by COVID-19 in the Global South. Today, the initiative has supplied 74 per cent of all COVID-19 vaccine doses supplied to low-income countries (LICs) during the pandemic; and in total, 52 of the 92 AMC-eligible economies relied on COVAX for more than half of their COVID-19 vaccine supply...

COVAX also deployed 2.5 million doses to protect the most vulnerable in humanitarian and conflict settings through a first-of-its kind mechanism called the Humanitarian Buffer, co-designed with international humanitarian organisations, and set up as a last resort to reach those who are not easily reached through government programmes. **Attempting to deliver novel products through non-governmental channels proved to be incredibly difficult,** but the effort provided deep insight into the systemic barriers that are exacerbated by a global emergency situation...

...With collaboration from manufacturers, all of COVAX's advance purchase supply agreements will have been completed or terminated by the end of 2023, with the exception of one, where a modest volume of supply will continue into the first half of 2024 in support of the new COVID-19 routine immunisation programme.

...some COVAX AMC funds remain in the contingency mechanism known as the Pandemic Vaccine Pool, and these can now be reinvested into translating the lessons from COVAX Facility into concrete actions. This includes the establishing of an African Vaccine Manufacturing Accelerator (AVMA), a result of our learnings from the pandemic where Africa was left vulnerable to supply restrictions. Investment in AVMA will make up to US\$ 1 billion available to support vaccine manufacturing on the African continent.

In addition, a First Response Fund will be established to ensure financing for a vaccine response is immediately available in the event of a future pandemic. It also includes funding "The Big Catch-up" effort designed to fill the gaps in immunisation resulting from the pandemic which are now causing outbreaks of vaccine-preventable diseases around the world and threatening the achievement of Immunization Agenda 2030 goals...

"COVID-19 has been the greatest health challenge of our time, and it was met with innovation and partnership on an equally unprecedented scale," said José Manuel Barroso, Chair of the Board of Gavi, the Vaccine Alliance. "COVAX's impact has been historic, as are the insights it has generated on how, concretely, the world can do better next time. As we transition COVID-19 into Gavi's routine programming, we do so with deep gratitude for the passion, dedication and sacrifice of so many around the globe who fought tirelessly for three years to try and create a more equitable world – and with an unwavering commitment to improve by transforming learnings into tangible action."...

"We knew that market forces alone would not deliver equitable access to vaccines and other tools," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "The creation of ACT-A and COVAX gave millions of people around the world access to vaccines, tests, treatments and other tools who would otherwise have missed out. COVAX has taught us valuable lessons that will help us to be better prepared for future epidemics and pandemics."

Notes to editors+

- Key Learnings – For a detailed overview on COVAX key learnings and recommendations for future pandemic preparedness and response, read this white paper: <https://www.gavi.org/news-resources/knowledge-products/covax-key-learnings-future-pandemic-preparedness-and-response>

Key learnings

[1] Equitable access requires an end-to-end solution that centres on public health, and the needs of the most vulnerable, at every step

[2] Hoarding, export restrictions and nationalism should be expected

[3] A successful global pandemic response involves taking risks

.....
.....

[Guiding principles for recovering, building resiliency, and strengthening of immunization in 2022 and beyond](#)

22 December 2023

PDF: <https://iris.who.int/bitstream/handle/10665/364944/9789240052772-eng.pdf?sequence=1>

Overview

In November 2020, WHO published guiding principles on immunization activities during the COVID-19 pandemic and other times of severe disruption. This document of guiding principles complements the 2020 document and similarly incorporates the IA2030 principles of being people-centred, country-owned, partnership-based and data-guided. These guiding principles intend to support countries in their decision-making and actions regarding immunization recovery, resiliency, and strengthening of immunization programmes in the context of the COVID-19 pandemic, including COVID-19 vaccination introduction and scale-up, and support efforts toward pandemic preparedness and building global health security.

Countries are encouraged to urgently close immunity gaps and recover immunization services while capitalizing on the opportunities from the pandemic response and COVID-19 vaccine roll-out to strengthen routine immunization services and increase resiliency in primary health care.



[WHO prequalifies a second malaria vaccine, a significant milestone in prevention of the disease](#)

21 December 2023 *News release Geneva*

WHO has added the R21/Matrix-M malaria vaccine to its [list of prequalified vaccines](#). In October 2023, [WHO recommended its use](#) for the prevention of malaria in children following the advice of the WHO Strategic Advisory Group of Experts (SAGE) on Immunization and the Malaria Policy Advisory Group. The prequalification means larger access to vaccines as a key tool to prevent malaria in children with it being a prerequisite for vaccine procurement by UNICEF and funding support for deployment by Gavi, the Vaccine Alliance.

The R21 vaccine is the second malaria vaccine prequalified by WHO, following the RTS,S/AS01 vaccine which obtained prequalification status in July 2022. Both vaccines are shown to be safe and effective in clinical trials, for preventing malaria in children. When implemented broadly, along with other recommended malaria control interventions, they are expected to have a high public health impact. Malaria, a mosquito-borne disease, places a particularly high burden on children in the African Region, where nearly half a million children die from the disease each year. Globally, in 2022, there were an estimated 249 million malaria cases and 608 000 malaria deaths across 85 countries.

The prequalification of the world's second malaria vaccine, developed by Oxford University and manufactured by Serum Institute of India, is poised to expand access to malaria prevention through vaccination. Demand for malaria vaccines is high but the supply has thus far been limited. The availability of two WHO recommended and prequalified malaria vaccines is expected to increase supply to meet the high demand from African countries and result in sufficient vaccine doses to benefit all children living in areas where malaria is a significant public health risk.



[The Pandemic Fund Announces Second Round of Funding with Half-a-Billion-Dollar Envelope](#)

WASHINGTON, Dec. 22, 2023 — The [Pandemic Fund's](#) Governing Board approved a grant envelope of \$500 million for its second round of **funding to help low- and middle-income countries scale up efforts to better prepare for future pandemics**. Interested [eligible countries, Regional Entities, and Implementing Entities](#) are invited to submit proposals through an online portal starting in late February through May 17, 2024.

In recognition of the high demand for funding under the first Call—considered a pilot Call, the second Call for Proposals will have a larger funding envelope and will again prioritize high-impact investments at national and regional level in early warning and disease surveillance systems, laboratory systems, and strengthening human resources and public health and community workforce capacity. **Particular attention will be paid to community and civil society engagement, gender equity, and other broader equity considerations as cross-cutting areas of focus in proposal development and implementation.**

The Pandemic Fund—a multi-stakeholder partnership—provides a dedicated stream of additional, long-term grant financing to strengthen critical pandemic prevention, preparedness, and response (PPR) capacities and capabilities in low- and middle-income countries. It has mobilized \$2 billion to date from 24 sovereign contributors and three philanthropies. The Fund is a collaborative effort between governments, the World Bank, the World Health Organization (WHO), other UN agencies, multilateral development banks (MDBs), global health initiatives, philanthropies, and civil society organizations..

.....
.....
.....

Polio – PHEIC

[Statement following the Thirty-seventh Meeting of the IHR Emergency Committee for Polio](#)

22 December 2023 *Statement*

[Closing section]

...Additional considerations

The Committee recognizes the concerns regarding the lengthy duration of the polio PHEIC and the importance of exploring alternative measures, including convening a polio IHR Review Committee to advise the WHO Director-General on the possible issuance of standing recommendations. The Committee noted the current review of the International Health Regulations taking place and that amendments to the Regulations were possible in 2024. **The Committee felt it was still too early to discontinue the PHEIC as the risk of exportation of both WPV and cVDPVs remains significant and the removal of the PHEIC may send the wrong message at this critical juncture in polio eradication.**

The Committee appreciates the commitment of the Afghan authorities to the global goal of polio eradication, and strongly encourages house to house campaigns be implemented wherever feasible as these campaigns enhance identification and coverage of zero dose and under-immunized children. The Committee noted and strongly supported the ongoing use of female vaccinators, enhancing access to households, with female participation as front line health workers increasing. The large number of returnees from Pakistan represents a significant risk of poliovirus spread, and the country programme needs to put in place risk mitigation measures and ensure vaccination of returning populations to the best possible extent. The committee urges a high-quality vaccination response take place immediately in the Southern Region of Afghanistan, to mitigate the risk of a large polio outbreak.

The Committee noted with concern the new transmission of WPV1 in Pakistan in areas such as Karachi and the Quetta Block, and calls for an aggressive outbreak response in the coming low transmission season, with a response synchronized between the two endemic countries to the maximum extent possible. The Committee commended the national and provincial

governments for demonstrating effective programme ownership in Pakistan. This must continue in the upcoming time of planned general elections, and maintenance of the effective roles of provincial chief secretaries, district commissioners and deputy commissioners is critical.

The Committee noted that Egypt is responding effectively to the cVDPV2 outbreak in North Sinai and urges Egypt to ensure this is maintained despite the effect of the war in Gaza which could put pressure on public health resources.

The Committee is concerned about the timeliness of detection of cVDPV2 in Mauritania, and urges Mauritania, Guinea and Mali to coordinate and synchronize activities. Zimbabwe should consider implementing environmental surveillance outside of the capital city Harare if feasible.

Nigeria remains central to stopping outbreaks in the African Region, as cVDPV2 from Nigeria has spread to many other African countries. Within Nigeria, programme quality issues have persisted since 2021, especially in the north-western part of the country. Stopping cVDPV outbreaks in Nigeria will be critical to success in the African Region and globally. The Committee is encouraged by the commitment of the new health leadership in the country and noted that political leadership at all levels in Nigeria must be aligned to address the chronic issues and improve the programme response quality. Lessons learnt from the Borno experience should be applied in the north-western states.

The Committee urged the polio program to strengthen all aspects of surveillance, noting that significant gaps remain in many affected countries, and to continue to address delays in specimens being transported for testing for polioviruses, leading to problems with specimen quality. Noting the challenges of polio surveillance particularly the timeliness of detection, the Committee recommends that the programme continues to strengthen and improve timeliness including by introducing direct detection methods.

Based on the current situation regarding WPV1 and cVDPVs, and the reports provided by affected countries, the Director-General accepted the Committee's assessment and on 21 December 2023 determined that the poliovirus situation continues to constitute a PHEIC with respect to WPV1 and cVDPV. The Director-General endorsed the Committee's recommendations for countries meeting the definition for 'States infected with WPV1, cVDPV1 or cVDPV3 with potential risk for international spread', 'States infected with cVDPV2 with potential risk for international spread' and for 'States previously infected by WPV1 or cVDPV within the last 24 months' and extended the Temporary Recommendations under the IHR to reduce the risk of the international spread of poliovirus, effective 21 December 2023.

.....

Polio this week as of 03 Jan 2024 - GPEI

Summary of new polioviruses this week, cases and positive environmental isolates:

- Pakistan: four WPV1-positive environmental samples
- DR Congo: two cVDPV1 cases, one cVDPV2 case and one cVDPV2-positive environmental sample
- Guinea: ten cVDPV2 cases
- Madagascar: one cVDPV1 case and one cVDPV1-positive environmental sample
- Mali: three cVDPV2 cases
- Niger: one cVDPV2 case
- South Sudan: one cVDPV2 case
- Tanzania: one cVDPV2 case

.....

.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

.....

WHO & Regional Offices [to 06 Jan 2024]

<https://www.who.int/news>

Selected News/Announcements/Statements

27 December 2023 Statement

[WHO teams deliver supplies to hospitals in Northern and Southern Gaza](#)

26 December 2023 Departmental news

[WHO to progress plans to develop a model for the medical \(care\) planning of mass gatherings](#)

22 December 2023 Statement

[Statement following the Thirty-seventh Meeting of the IHR Emergency Committee for Polio](#)

21 December 2023 Departmental news

[Public consultation on antimicrobial manufacturing effluent guidance](#)

21 December 2023 Departmental news

[Advancing the One Health Agenda with a focus on environment](#)

21 December 2023 Statement

[Lethal combination of hunger and disease to lead to more deaths in Gaza](#)

21 December 2023 Departmental news

[Message by the Director of the Department of Immunization, Vaccines and Biologicals at WHO - November/December 2023](#)

21 December 2023 News release

[WHO prequalifies a second malaria vaccine, a significant milestone in prevention of the disease](#)

20 December 2023 Departmental news

[WHO and UNICEF publish new psychological intervention to support adolescents and their caregivers](#)

19 December 2023 Statement

[COVID-19 vaccinations shift to regular immunization as COVAX draws to a close](#)

19 December 2023 Joint News Release

[New South-South health cooperation initiative launched linking Africa and the Caribbean](#)

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region

No new digest content identified.

WHO Region of the Americas PAHO

:: 27 Dec 2023

[2023 Highlights - PAHO focuses on primary health care, communicable diseases, and pandemic preparedness](#)

Washington D.C. 27 December 2023 (PAHO) – As the year draws to a close, it is time to reflect upon some of highlights from the Pan American Health Organization (PAHO), as well as major advances towards health in the Region of the Americas: Dr. Barbosa begins his tenure as PAHO Director – On 31st January, Dr. Jarbas Barbosa was sworn in as new...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

:: [Connecting maps, data and health: introducing the WHO European Geospatial Coordination Hub](#)
5 January 2024

WHO Eastern Mediterranean Region EMRO

:: [WHO builds health emergency response capacities](#) 25 December 2023

:: [WHO and Russian Federation collaborate to strengthen emergency response capacities in Islamic Republic of Iran](#) 24 December 2023

WHO Western Pacific Region

:: 2 January 2024

[Affordable, accessible health care gets results: financial protection and people-centred care in Malaysia](#)

.....

WHO - Emergency situation reports

4 January 2024

[Situation Report: Greater Horn of Africa Food Insecurity and Health - Grade 3 Emergency — 1 September - 31 October 2023](#)

Overview

- Countries in the Horn are experiencing increased rainfall resulting in flooding and river overflows influenced by El-Niño and a positive Indian Ocean Dipole. This has resulted in the displacement of hundreds of thousands of people, cutting off road networks, damaging infrastructure and affecting human health.
- 49.3 million people in the region are food insecure (IPC3+) experiencing crisis levels of acute food insecurity and above; 8.2 million people are in IPC phase 4 and 43,000 in IPC phase 5 (South Sudan).
- More than 11.1 million children under the age of five are suffering from acute malnutrition, of which 2.7 million will require treatment for severe acute malnutrition in 2023.
- Over 19.4 million people have been displaced due to conflict, drought, and flooding. Out of these 14.5 million are internally displaced, while 4.5 million are refugees and asylum seekers (as of 30 September 2023). Out of the total number of IDPs, 10.1 million were displaced due to conflict and 4.4 million due to natural disaster.

- Admission trends for severe acute malnutrition (SAM) have shown a decrease in the majority of countries in the region which can likely be attributed to improved pasture, but also to a reduction of outreach activities (funding shortages) and flooding affecting the access to health services.
- Between January and October 2023, compared to the same period in 2022, there were over 43% (155,480) more SAM admissions in Somalia, and 38% (28,705) more in Kenya, 9% (over 19,000) more in South Sudan, and 11% (461) more admissions in Djibouti.
- The region is battling with multiple outbreaks of diseases including cholera in four countries, measles and malaria in all seven countries, and dengue fever in Ethiopia, Djibouti, Sudan and Somalia. In Sudan, a cholera outbreak was declared on 26th September 2023 in Gedaref state, and in South Kordofan and Khartoum state on 7th October 2023.
- WHO continues to provide support on leadership and coordination, surveillance and health information, outbreak prevention and control, essential nutrition actions and health services.

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

Dengue - Global situation

21 December 2023

Global Overview

Current situation

The global incidence of dengue has markedly increased over the past two decades, posing a substantial public health challenge. From 2000 to 2019, the World Health Organization (WHO) documented a ten-fold surge in reported cases worldwide increasing from 500 000 to 5.2 million. The year 2019 marked an unprecedented peak, with reported instances spreading across 129 countries.

After a slight decline of cases between the year 2020-2022 due to the COVID-19 pandemic and lower reporting rate, **in 2023, an upsurge in dengue cases have been observed globally, characterized by a significant increase in the number, scale, and simultaneous occurrence of multiple outbreaks, spreading into regions previously unaffected by dengue.**

Dengue transmission is cyclic and large outbreaks every 3-4 years can be expected. During the COVID-19 pandemic we saw moderate transmission of dengue in some regions and low transmission in others leading to an accumulation of people without immunity to certain dengue virus serotypes. However, the data on the circulating dengue serotypes is limited.

Since the beginning of 2023, ongoing transmission, combined with an unexpected spike in dengue cases have resulted in close to a historic high of over five million cases and more than 5000 dengue-related deaths reported in over 80 countries/territories and five WHO regions: Africa, Americas, South-East Asia, Western Pacific and Eastern Mediterranean Regions globally (Figure 1). Close to 80% of these cases, or 4.1 million, have been reported in the Region of the Americas. Dengue is the most widespread arbovirus and causes the highest number of arboviral disease cases in the Region of the Americas, with cyclic epidemics recurring every 3 to 5 years. In addition, clusters of autochthonous dengue have been reported in the WHO European Region. However, these numbers are likely an underestimate of the true burden as most of the primary infections are asymptomatic and dengue reporting is not mandatory in many countries.

Several factors are associated with the increasing risk of spread of the dengue epidemic including, the changing distribution of the vectors (chiefly *Aedes aegypti* and *Aedes albopictus*), especially in previously dengue naïve countries; the consequences of El Nino phenomena in 2023 and climate change leading to increasing temperatures and high rainfall, humidity among others; fragile health systems in the midst of COVID-19 pandemic, political and financial instabilities in countries facing complex humanitarian crises and high population movements. These factors also challenge the response to the epidemic and the risk of further spread to other countries. Weakness in the surveillance systems in many affected countries may have led to delayed reporting and response and missed identification of symptoms, contributing to increased severe dengue outcomes.

WHO has assessed the risk to be high globally considering the increasing risk of transmission and the upsurge of cases and deaths.

.....

Weekly Epidemiological Record

<https://www.who.int/publications/journals/weekly-epidemiological-record>

[Vol. 98, No. 52, pp. 677–696 29 December 2023](#)

<https://iris.who.int/bitstream/handle/10665/375358/WER9852-eng-fre.pdf>

:: Implementation of preventive chemotherapy (PC) against neglected tropical diseases (NTDs) in 2022 and status of donated medicines for NTDs in 2022–2023

.....

New WHO Publications

<https://www.who.int/publications/i>

Selected

29 December 2023

[Global update on implementation of preventive chemotherapy \(PC\) against neglected tropical diseases...](#)

22 December 2023

[Guiding principles for recovering, building resiliency, and strengthening of immunization in 2022 and...](#)

22 December 2023

[Schistosomiasis and soil-transmitted helminthiases: progress report, 2022](#)

22 December 2023

[Regional workshop on Invasive Bacterial Disease \(IBD\) surveillance, New Delhi, India, 20 December 2022](#)

22 December 2023

[Regional Workshop on lot release of COVID-19 vaccines Kasauli, India, 10–14 October 2022](#)

21 December 2023

[Infection prevention and control guideline for coronavirus disease 2019 \(COVID-19\): Executive summary,...](#)

21 December 2023

[Infection prevention and control in the context of COVID-19: a guideline, 21 December 2023](#)

19 December 2023

[Policy brief on person-centred monitoring to focus prevention and guide programmes](#)

19 December 2023

[Policy brief on digital health data](#)

19 December 2023

[Policy brief on integrating and strengthening monitoring of differentiated ART service delivery](#)

18 December 2023

[Operational guidance on the use of yellow fever assays in the context of surveillance](#)

18 December 2023

[Evaluation of WHO normative function at country level: report](#)

18 December 2023

[WHO fourth global infodemic management conference: advances in social listening for public health, May...](#)

.....
.....

USA – HHS, FDA, CDC

HHS

News

No new digest content identified.

FDA

Press Announcements

No new digest content identified.

FDA VRBPAC

Advisory Committee Calendar

No new meetings scheduled.

CDC/ACIP [U.S.] [to 06 Jan 2024]

<http://www.cdc.gov/media/index.html>

Latest News Releases

No new digest content identified.

ACIP Meetings

Next ACIP Meeting

No new meetings scheduled.

MMWR Weekly

<https://www.cdc.gov/mmwr/index2023.html>

January 5, 2024 / No. 52-53

[PDF of this issue](#)

- [Second Nationwide Tuberculosis Outbreak Caused by Bone Allografts Containing Live Cells — United States, 2023](#)

- Notes from the Field: Supply Interruptions of First- and Second-Line Oral Drugs to Treat Tuberculosis During the Previous 12 Months — California, January–March, 2023

December 22, 2023 / No. 51

[PDF of this issue](#)

- SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals
- Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials — United States and International Sites, 2021–2022
- Coverage with Influenza, Respiratory Syncytial Virus, and Updated COVID-19 Vaccines Among Nursing Home Residents – National Healthcare Safety Network, United States, December 2023
- Influenza, Updated COVID-19, and Respiratory Syncytial Virus Vaccination Coverage Among Adults — United States, Fall 2023

.....
.....

Europe

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

No new digest content identified.

.....

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

No new digest content identified.

.....
.....

Africa CDC [to 06 Jan 2024]

<http://www.africacdc.org/>

Press Releases, Statements [Selected]

[The 3rd African Hepatitis Summit: "Putting Africa on Track towards Viral Hepatitis Elimination"](#)

20 December 2023

.....
.....

China CDC

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 06 Jan 2024]

<http://en.nhc.gov.cn/>

News

No new digest content identified.

National Medical Products Administration – PRC [to 06 Jan 2024]

<http://english.nmpa.gov.cn/>

News

[National health response teams capable of covering all provincial regions of China](#)

2024-01-02

All provincial and 90 percent of municipal disease control centers have nucleic acid detection and virus isolation capabilities, Wang Hesheng, deputy head of the National Health Commission and chief of the National Disease Control and Prevention Administration, said during a press conference.

China CDC Weekly Reports: Current Volume (6)

2024-01-05 / No. 1

[View PDF of this issue](#)

- [Preplanned Studies: Diagnosis, Treatment, and Associated Factors Among Patients with HCV Infection — Jiangsu Province, China, 2004–2020](#)
- [Vital Surveillances: Temporal and Spatial Trends in HIV Positivity Rate for VCT Clinics — China, 2015–2022](#)
- [Review: Evolution of HIV/AIDS Prevention and Control Policies in China: A Grounded Theory Approach](#)
- [Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, November 2023*](#)

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Organization Announcements

Paul G. Allen Frontiers Group [to 06 Jan 2024]

<https://alleninstitute.org/news-press/>

News

No new digest content identified.

BMGF - Gates Foundation [to 06 Jan 2024]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 06 Jan 2024]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of

mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people
News: Articles and Publications
No new digest content identified.

CARB-X [to 06 Jan 2024]

<https://carb-x.org/>

News

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 06 Jan 2024]

<http://cepi.net/>

Latest News

[CEPI partners with Lemonex to advance mRNA vaccine delivery against future pandemic threats](#)

Lemonex's mRNA drug delivery technology, DegradaBALL®, could minimise post-mRNA vaccination side effects and improve access to future mRNA vaccines.

End Pandemics

04 Jan 2024

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 06 Jan 2024]

<https://cioms.ch/>

News; Publications; Events

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 06 Jan 2024]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 06 Jan 2024]

<https://dukeghic.org/>

News

No new digest content identified.

EDCTP [to 06 Jan 2024]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

No new digest content identified.

Emory Vaccine Center [to 06 Jan 2024]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 06 Jan 2024]

<http://www.euvaccine.eu/>

Latest News, Events

No new digest content identified.

Evidence Aid [to 06 Jan 2024]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

<http://www.evidenceaid.org/>

Resources [Selected]

[**Interventions to improve vaccination delivery during protracted humanitarian crises**](#)

Added January 4, 2024

[**Wellbeing of migrant and refugee parents from the Middle East**](#)

Added January 3, 2024

[**Strategies to improve disaster risk management in hospitals**](#)

Added January 2, 2024

[**Respiratory pandemics and urban planning**](#)

Added December 29, 2023

Fondation Merieux [to 06 Jan 2024]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 06 Jan 2024]

<https://www.gavi.org/>

News Releases

19 December 2023

[**COVID-19 vaccinations shift to regular immunisation as COVAX draws to a close**](#)

GE2P2 Global Foundation [to 06 Jan 2024]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – January 2024](#)

:: [Genomic Medicine – Governance, Ethics, Policy, Practice: A Monthly Digest](#) – Oct 2023

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 24 Oct 2023 – Issue 09](#)

GHIT Fund [to 06 Jan 2024]

<https://www.ghitfund.org/newsroom/press>

Press Releases

December 18, 2023

[**EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children. GHIT has financed the Pediatric Praziquantel Consortium's development of arpraziquantel since 2013, investing 1.85 billion yen**](#)

Global Fund [to 06 Jan 2024].

<https://www.theglobalfund.org/en/news/>

News & Stories

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 06 Jan 2024]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 06 Jan 2024]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 06 Jan 2024]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [to 06 Jan 2024]

<http://www.humanvaccinesproject.org/>

News

No new digest content identified.

IAVI [to 06 Jan 2024]

<https://www.iavi.org/>

News, Features

Features

[**IAVI recommends new business models for increasing access to monoclonal antibodies**](#)

January 4, 2024

New approaches could help advance access to a promising medical innovation, consortium finds.

INSERM [to 06 Jan 2024]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICH - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use [to 06 Jan 2024]

<https://www.ich.org/page/press-releases>

News/Pubs/Press Releases [Selective]

No new digest content identified.

ICRC [to 06 Jan 2024]

<https://www.icrc.org/en/whats-new>

What's New [Selected]

No new digest content identified.

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

[HPV vaccinations rebound in 2023](#)

20 Dec 2023

US\$ 92 million in funding from IFFIm supports Gavi programme.

IFRC [to 06 Jan 2024]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press Releases [Selected]

Press release 03/01/2024

[Red Cross swings into action immediately after Japan earthquake](#)

Institut Pasteur [to 06 Jan 2024]

<https://www.pasteur.fr/en/press-area>

Press Documents

Press release

05.01.2024

[Sensorion Announces Partnership with the Institut Pasteur to Accelerate Gene Therapy Programs Targeting Hearing Disorders has been Extended for Five Years](#)

ISC / International Science Council [to 06 Jan 2024]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

News, Blogs

No new digest content identified.

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News/Events [Selected]

No new digest content identified.

IVAC [to 06 Jan 2024]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 06 Jan 2024]

<http://www.ivi.int/>

IVI News & Announcements

[Euvichol-S, simplified formulation of oral cholera vaccine, licensed by Korean regulatory agency](#)

[2023 Year in Review](#)

[IVI hosts a Cholera Vaccine Research Day on the 10th anniversary of the creation of the oral cholera vaccine global stockpile](#)

Johns Hopkins Center for Health Security [to 06 Jan 2024]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

December 19:

[Johns Hopkins Center for Health Security publishes key takeaways from its meeting on the convergence of AI and biotechnology](#)

MSF/Médecins Sans Frontières [to 06 Jan 2024]

<http://www.msf.org/>

Latest [Selected Announcements]

No new digest content identified.

National Academy of Medicine - USA [to 06 Jan 2024]

<https://nam.edu/programs/>

News [Selected]

No new digest content identified.

National Academy of Sciences - USA [to 06 Jan 2024]

<https://www.nationalacademies.org/newsroom?>

News

No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 06 Jan 2024]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

February 22-23, 2024 (Virtual)

NIH [to 06 Jan 2024]

<http://www.nih.gov/>

News Releases

No new digest content identified.

PATH [to 06 Jan 2024]

<https://www.path.org/media-center/>

Newsroom

No new digest content identified.

Rockefeller Foundation [to 06 Jan 2024]

<https://www.rockefellerfoundation.org/>

Press Releases and Speeches

No new digest content identified.

Sabin Vaccine Institute [to 06 Jan 2024]

<https://www.sabin.org/press/>

Latest News & Press Releases

No new digest content identified.

UNAIDS [to 06 Jan 2024]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

No new digest content identified.

UNICEF [to 06 Jan 2024]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements

Press release 05 January 2024

[Intensifying conflict, malnutrition and disease in the Gaza Strip creates a deadly cycle that threatens over 1.1 million children](https://www.unicef.org/press-releases/intensifying-conflict-malnutrition-and-disease-gaza-strip-creates-deadly-cycle)

<https://www.unicef.org/press-releases/intensifying-conflict-malnutrition-and-disease-gaza-strip-creates-deadly-cycle>

NEW YORK, 5 January 2024 – Children in the Gaza Strip face a deadly triple threat to their lives, as cases of diseases rise, nutrition plummets and the escalation in hostilities approaches its fourteenth week. Thousands of children have already died from the violence, while living conditions for children continue to rapidly deteriorate, with...

Press release 27 December 2023

[Hundreds of vulnerable children evacuated for second time as Sudan war continues to put millions of children at risk](https://www.unicef.org/press-releases/hundreds-vulnerable-children-evacuated-second-time-sudan-war-continues-put-millions)

<https://www.unicef.org/press-releases/hundreds-vulnerable-children-evacuated-second-time-sudan-war-continues-put-millions>
PORT SUDAN/NEW YORK, 27 December 2023 – 253 babies and children have been safely evacuated from transit centres in Wad Madani, Sudan to a safer location in the country, after fighting in Al Jazirah state erupted this month. For many of the children, this is the second time they have been evacuated after they were evacuated from Mygoma orphanages...

22 December 2023

[Statement by UNICEF on the risk of famine in the Gaza Strip](https://www.unicef.org/press-releases/statement-unicef-risk-famine-gaza-strip)

<https://www.unicef.org/press-releases/statement-unicef-risk-famine-gaza-strip>
NEW YORK, 22 December 2023 – “Yesterday, the Integrated Food Security Phase Classification (IPC) warned the world of the very high risk of famine in the Gaza Strip, increasing every day if the situation persists. Specifically, the IPC report said at least 1 in 4 households in the Gaza Strip, or more than half a million people, are facing...

[COVID-19 vaccinations shift to regular immunisation as COVAX draws to a close](https://www.unicef.org/press-releases/covid-19-vaccinations-shift-regular-immunisation-covax-draws-close)

<https://www.unicef.org/press-releases/covid-19-vaccinations-shift-regular-immunisation-covax-draws-close>
COVAX will close 31 December 2023 having delivered nearly 2 billion doses of vaccines to 146 economies, and averted an estimated 2.7 million deaths in AMC lower-income participating economies. COVAX’s end-to-end efforts helped lower-income economies

Unitaid [to 06 Jan 2024]

<https://unitaid.org/>

Featured News

19 December 2023

[Unitaid awards US\\$24 million in funding to address intellectual property-related barriers to health technologies](#)

With new grants issued to three organizations, Unitaid will continue to support work on the use of TRIPS flexibilities – internationally agreed legal mechanisms allowing countries to overcome or reduce the potential negative impact of patents in response to specific public health needs – to enable equitable access to critical health products in low- and middle-income countries (LMICs). This work aims to ensure the products are affordable and available to everyone in LMICs who needs them.

Before the COVID-19 pandemic began, a World Health Organization publication estimated that as many as two billion people lacked access to essential medicines. Then the pandemic overloaded health systems and set back progress on diseases such as HIV, tuberculosis (TB), malaria, and hepatitis C, among others. It also laid bare profound disparities in the way that health research is conducted and how access to innovation is determined.

Without intervention, inequitable access will only widen, and populations that are already vulnerable and marginalized will face increasing risk of disease, poverty, reduced quality of life and even death.

Working in partnership with the International Treatment Preparedness Coalition (ITPC), Third World Network (TWN), and Wemos, Unitaid will contribute to equitable access to health products of public health importance by improving affordability, building capacity and improving supply of key tools for HIV, TB, hepatitis C, cervical cancer, and public health emergencies, in complementarity with other access strategies such as voluntary licenses.

18 December 2023

[The Government of Korea triples its contribution to global health organization Unitaid in 2023](#)

Vaccine Equity Cooperative [nee Initiative] [to 06 Jan 2024]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 06 Jan 2024]

<https://www.vaccineacceptance.org/>

Announcements, Blog

No new digest content identified.

Vaccine Confidence Project [to 06 Jan 2024]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 06 Jan 2024]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

[January 2024: Vaccines and Infectious Diseases in the News](#)

Happy New Year! It seems that the pathogens causing infectious diseases did not “get the memo” about the holidays! Indeed, as we turn the calendars, you may be visiting our site for information about one of several recent topics of attention. Find out more or get our resources related to:

- Fall respiratory viruses (Influenza, COVID-19 and RSV)
- Measles
- Misinformation about DNA fragments in COVID-19 mRNA vaccines

Wellcome Trust [to 06 Jan 2024]

<https://wellcome.org/>

News, Opinion, Reports

No new digest content identified.

The Wistar Institute [to 06 Jan 2024]

<https://www.wistar.org/news/press-releases>

Press Releases

Jan. 4, 2024

[The Wistar Institute Recruits Dr. Filippo Veglia to the Ellen and Ronald Caplan Cancer Center](#)

Brain cancer researcher joins faculty as assistant professor.

World Bank [to 015 Oct 2022]

<http://www.worldbank.org/en/news/all>

All News [Selected]

[The Pandemic Fund Announces Second Round of Funding with Half-a-Billion-Dollar Envelope](#)

WASHINGTON, Dec. 22, 2023 — The Pandemic Fund's Governing Board approved a grant envelope of \$500 million for its second round of funding to help low- and middle-income countries scale up efforts to better prepare for future pandemics. Interested eligible countries, Regional Entities, and Implementing Entities are invited to submit proposals through an online portal starting in late February through May 17, 2024...

[A One Health Approach to Boost Health Security in Western and Central Africa](#)

WASHINGTON, December 19, 2023 - The World Bank Board today approved a Health Security Program for Western and Central Africa in a move to boost health security in the sub-region. During its first phase, the \$500 million IDA* financed multiphase operation will involve Cabo Verde, Guinea, Liberia, and the Economic Community of West African States (ECOWAS) to increase collaboration and improve health system capacities to prevent, detect, and respond to health emergencies in the region. The Program will also leverage financing from other partners, namely the Global Financing Facility for Women, Children and Adolescents, and the Pandemic Fund...

WFPHA: World Federation of Public Health Associations [to 06 Jan 2024]

<https://www.wfpha.org/>

No new digest content identified.

World Medical Association [WMA] [to 06 Jan 2024]

<https://www.wma.net/news-press/press-releases/>

Press Releases

No new digest content identified.

World Organisation for Animal Health [to 06 Jan 2024]

<https://www.oie.int/en/>

Press Releases, Statements

Statements

[Avian influenza vaccination: why it should not be a barrier to safe trade](#)

Published on 28 December 2023

Since 2005, avian influenza has had a staggering toll, with over 500 million birds lost to the disease worldwide. Its devastating impact extends beyond domestic and wild birds, threatening livelihoods, food security and public health.

.....

ARM [Alliance for Regenerative Medicine] [to 06 Jan 2024]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 06 Jan 2024]

<https://www.bio.org/press-releases>

Press Releases

[BIO and ICBA Release Updated Report on Biotechnology's Role in Meeting UN Sustainable Development Goals](#)

December 21, 2023

The Biotechnology Innovation Organization (BIO) released an updated report produced in partnership with the International Council of Biotechnology Associations (ICBA) that highlights biotechnology's role in meeting the United Nations' 17 SDGs...

DCVMN – Developing Country Vaccine Manufacturers Network [to 06 Jan 2024]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 06 Jan 2024]

<https://internationalbiotech.org/news/>

News

No new digest content identified.

IFPMA [to 06 Jan 2024]

<https://ifpma.org/>

Selected Press Releases/Statements

No new digest announcements identified

International Alliance of Patients' Organizations – IAPO [to 06 Jan 2024]

<https://www.iapo.org.uk/news>

Press and media [Selected]

[**Joint statement calling for governments to strengthen home support for patients with advanced diseases**](#)

Friday, 5 January 2024

Home support for patients with advanced diseases and their families: joint statement from international patient, carer and palliative care associations

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

[**Vinita Gupta and Lucas Sigman appointed 2024 Chair and Vice-Chair of the IGBA CEO Advisory Committee \(December 2023\)**](#)

The International Generic and Biosimilar medicines Association (IGBA) announced today the annual leadership change of its CEO Advisory Committee (AC). Vinita Gupta, CEO of Lupin, was appointed Chair and Lucas Sigman, CEO of Insud Pharma, Vice-Chair.

PhRMA [to 06 Jan 2024]

<http://www.phrma.org/>

Press Releases

No new digest announcements identified

.....

.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca

Press Releases

Latest

[Beyfortus approved in China for the prevention of RSV disease in infants](#)

02 January 2024

First and only RSV preventive option authorised for use in China

[AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases](#)

26 December 2023

Bharat Biotech

Press Releases - *No new digest announcements identified.*

BioCubaFarma – Cuba

Últimas Noticias - *No new digest announcements identified*

Biological E

News - *No new digest announcements identified*

BioNTech

Press Releases - *No new digest announcements identified.*

Boehringer

Press Releases - *No new digest announcements identified.*

CanSinoBIO

News - *Website not responding at inquiry*

CIGB

Latest News - *No new digest announcements identified.*

Cinnagen

Recent News - *No new digest announcements identified.*

Clover Biopharmaceuticals - China

News - *No new digest announcements identified.*

Curevac [Bayer Ag – Germany]

News

January 5, 2024

[CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform](#)

- Head-to-head comparison with licensed bivalent mRNA-based comparator vaccine confirms competitive immune responses at lower doses and favorable tolerability profile
- Monovalent mRNA vaccine candidate, CV0601, encoding Omicron BA.4-5 variant and bivalent candidate, CV0701, encoding Omicron BA.4-5 variant as well as the original SARS-CoV-2 virus, successfully boosted antibody titers and were generally well tolerated across all tested dose levels

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified

<https://sputnikvaccine.com/> - No new digest announcements identified

GSK

[Press releases for media](#) - No new digest announcements identified

IMBCAMS, China

[Home](#) - Website not responding at inquiry.

Janssen/JNJ

[Press Releases](#) - No new digest announcements identified

Merck

[News releases](#)

[FDA Grants Priority Review to Merck's New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults](#)

Dec 19, 2023

Moderna

[Press Releases](#) - No new digest announcements identified

Nanogen

[News](#) - No new digest announcements identified

Novartis

[News](#) - No new digest announcements identified.

Novavax

[Press Releases](#)

Dec 21, 2023

Statement Malaria

[R21/Matrix-M™ Malaria Vaccine Granted Prequalification by World Health Organization](#)

Dec 19, 2023

Statement COVID-19

[Novavax's Updated COVID-19 Vaccine Now Available in Canada](#)

Dec 19, 2023

Statement COVID-19

[Novavax's Updated COVID-19 Vaccine Now Available in France](#)

Dec 18, 2023 *COVID-19*

[Novavax's Updated COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan](#)

Pfizer

[Recent Press Releases](#) - No new digest announcements identified.

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

[Press Releases](#) - No new digest announcements identified.

Serum Institute of India

[NEWS & ANNOUNCEMENTS](#) - No new digest announcements identified

Sinopharm/WIBPBIBP

[News](#) - No new digest announcements identified *[English translation function not operating]*

Sinovac

[Press Releases](#) - No new digest announcements identified.

SK Biosciences

[Press Releases](#) - No new digest announcements identified.

Takeda

[Newsroom](#) - No new digest announcements identified.

Valneva

[Press Releases](#) - No new digest announcements identified.

Vector State Research Centre of Virology and Biotechnology

[Home](#) - Website not responding [404 error]

WestVac Biopharma

[Media](#)

[Caring for the disaster-stricken area, helping one another in the relief work | WestVac Biopharma wastes no time in supplying the trivalent XBB COVID-19 vaccine to Linxia Prefecture, Gansu Province](#)

2023-12-26

On December 18 at 23:59, a 6.2-magnitude earthquake with a depth of 10 kilometers struck the Bonan-Dongxiang-Salar autonomous county of Jishishan in Linxia Hui Autonomous Prefecture, Gansu Province, China.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[Website](#) *[No News/Announcements page identified]*

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 14, 2023 Issue 4

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 26, Number 1: E1-96 Jan 2024

<https://journalofethics.ama-assn.org/issue/health-and-loneliness>

Critical Pedagogies in Health Professions Education

Health professions training is mainly competency driven, with students' and trainees' learning and technical skill development regularly assessed, usually in terms of standardized outcomes. Yet, there are good ethical and clinical questions to ask about competency-based medical education, specifically about how schools' and academic health centers' curricula meaningfully motivate learning and skill development about social privilege, health equity, and structural determinants of patients' health and health outcomes. This theme issue considers whether and to what extent skill development about, for example, the affective features of, say, coming to terms with one's privilege is teachable and assessable in competency-based frameworks, especially when those frameworks have a history of excluding key perspectives. Critical pedagogies investigated herein suggest strategies for interrogating teaching and learning methods and curricular content that are socially, culturally, politically, and historically fraught.

American Journal of Human Genetics

Jan 04, 2024 Volume 111 Issue 1 p1-210

<https://www.cell.com/ajhg/current>

This Month in The Journal

Alyson B. Barnes, Kylee L. Spencer, Sara B. Cullinan

Biobanks are becoming increasingly common, and although each has its own goals, strengths, and challenges, the standard recipe is a focus on scientific discovery through genetic data linked to electronic health records (EHRs). In this issue, Wiley et al. describe the development of the Colorado Center for Personalized Medicine Biobank (CCPM Biobank), which is not only designed to advance research but also to directly impact patient care. A few key elements were crucial to achieving these dual aims.

Perspective

Will variants of uncertain significance still exist in 2030?

Douglas M. Fowler, Heidi L. Rehm

The authors propose that many, if not most, variants of uncertain significance (VUSs) in coding regions will be resolved by 2030 and outline a confluence of changes making this possible. They note that achieving this goal will depend on the choices made now and in the next few years.

American Journal of Infection Control

January 2024 Volume 52 Issue 1 p1-140

<http://www.ajicjournal.org/current>

Brief Reports

[Most liked #monkeypox videos on TikTok: Implications for infection control](#)

Corey H. Basch, Bhavya Yalamanchili, Joseph Fera, Sandhya Narayanan

Published online: July 06, 2023

Commentary

[Category A waste processing and disposal is a critical weakness in the United States response plans for outbreaks of high consequence infectious diseases](#)

Shawn G. Gibbs, et al.

Published online: September 04, 2023

American Journal of Preventive Medicine

January 2024 Volume 66 Issue 1 p1-194

<https://www.ajpmonline.org/current>

Research Briefs

[Estimating the Population Newly Eligible for the Pneumococcal Conjugate Vaccine](#)

Erica Chilson, et al.

Published online: September 04, 2023

p164-168 Open Access

Research Letters

[Reporting of Race and Ethnicity in the Vaccine Safety Datalink, 2011–2022](#)

Kate E. Kurlandsky, et al.

Published online: September 03, 2023

p182-184

American Journal of Public Health

January 2024 114(1)

<http://ajph.aphapublications.org/toc/ajph/current>

[New issue; No digest content identified]

American Journal of Tropical Medicine and Hygiene

Volume 110 (2024): Issue 1 (Jan 2024)

<https://www.ajtmh.org/view/journals/tpmd/110/1/tpmd.110.issue-1.xml>

Review Articles

Open access

[Systematic Review and Meta-Analysis of Seasonal Malaria Chemoprevention](#)

Julie Thwing, et al.

Volume/Issue: [Volume 110: Issue 1](#)

Article Category: Review Article

DOI: <https://doi.org/10.4269/ajtmh.23-0481>

Annals of Internal Medicine

December 2023 Volume 176, Issue 12

<https://www.acpjournals.org/toc/aim/current>

Ideas and Opinions

[Communicating the Value of Influenza Vaccines to Patients: Translating Vaccine Effectiveness to Acceptance](#)

Mark W. Tenforde, MD, PhD, MPH, DTM&H, Fatimah S. Dawood, MD, Sascha R. Ellington, PhD, MSPH, ... et al.

Pages: 1670–1671

Artificial Intelligence – An International Journal

Volume 324 November 2023

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/324/suppl/C>

[Site under maintenance at inquiry]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 06 Jan 2024)

[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 06 Jan 2024)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 06 Jan 2024)

[Prevalence of HIV in slums area: a systematic review and meta-analysis](#)

Human Immunodeficiency Virus (HIV) remains a significant global health burden, particularly affecting vulnerable populations residing in slum areas which is characterized by overcrowding, poverty, and limited ...

Authors: Meysam Behzadifar, Seyed Jafar Ehsanzadeh, Banafshe Darvishi Teli, Samad Azari, Ahad Bakhtiari and Masoud Behzadifar

Content type: Research 5 January 2024

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 06 Jan 2024)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 06 Jan 2024)
[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 06 Jan 2024)
[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 06 Jan 2024)

[Information needs of ethnically diverse, vaccine-hesitant parents during decision-making about the HPV vaccine for their adolescent child: a qualitative study](#)

The English schools-based human papillomavirus (HPV) vaccination programme has the potential to eliminate HPV-related cancers if high uptake is achieved. However, unmet information needs among some parents may...

Authors: Harriet Fisher, Sarah Denford, Suzanne Audrey, Adam Finn, Huda Hajinur, Matthew Hickman, Sandra Mounier-jack, Asha Mohamed, Marion Roderick, Leanne Tucker, Julie Yates and Tracey Chantler

Citation: BMC Public Health 2024 24:91

Content type: Research Published on: 4 January 2024

[The impact of internet health information seeking on COVID-19 vaccination behavior in China](#)

Amid the COVID-19 pandemic, the significance of vaccination has been emphatically underscored. As the foremost and pivotal measure for preventing COVID-19 transmission, the COVID-19 pneumonia vaccine plays an ...

Authors: Yunyun Zhang, Lidong Zhang, Hongyu Guan, Rong Hao and Wenting Liu

Citation: BMC Public Health 2024 24:89

Content type: Research Published on: 4 January 2024

[Prevalence of intentions to receive monkeypox vaccine. A systematic review and meta-analysis](#)

Immunization, as a preventive strategy against infectious diseases, has consolidated its position as a fundamental pillar in the field of public health. Therefore, the present study aimed to determine the prev...

Authors: Darwin A. León-Figueroa, Joshuan J. Barboza, Mario J. Valladares-Garrido, Ranjit Sah and Alfonso J. Rodriguez-Morales

Citation: BMC Public Health 2024 24:35

Content type: Research Published on: 2 January 2024

[Global, regional and national trends in tuberculosis incidence and main risk factors: a study using data from 2000 to 2021](#)

Despite the significant progress over the years, Tuberculosis remains a major public health concern and a danger to global health. This study aimed to analyze the spatial and temporal characteristics of the in...

Authors: Wentao Bai and Edward Kwabena Ameyaw

Citation: BMC Public Health 2024 24:12

Content type: Research Published on: 2 January 2024

[Global COVID-19 vaccine acceptance level and its determinants: an umbrella review](#)

The COVID-19 vaccination is essential for reducing disease burden on a worldwide scale. The success of this strategy will largely depend on how well vaccines are received. Previous reviews had produced contrad...

Authors: Biruk Beletew Abate, Befkad Derese Tilahun and Berihun Mulu Yayeh

Citation: BMC Public Health 2024 24:5

Content type: Research Published on: 2 January 2024

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 06 Jan 2024)

[No new digest content identified]

BMJ Evidence-Based Medicine

December 2023 - Volume 28 - 6

<https://ebm.bmj.com/content/28/6>

[Reviewed earlier]

BMJ Global Health

January 2024 - Volume 9 - 1

<https://gh.bmj.com/content/9/1>

Analysis

[Lessons learnt from COVID-19 to reduce mortality and morbidity in the Global South: addressing global vaccine equity for future pandemics](#) (1 January, 2024)

Rebecca Martin, Allan Maleche, Jill Gay, Haram Fatima

Original research

[Convergence of HIV and non-communicable disease epidemics: geospatial mapping of the unmet health needs in an HIV hyperendemic community in South Africa](#) (4 January, 2024)

Diego F Cuadros, Chayanika Devi, Urisha Singh, Stephen Olivier, Alison C Castle, Yumna Moosa, Johnathan A Edwards, Hae-Young Kim, Mark J Siedner, Emily B Wong, Frank Tanser

Practice

[Mentorship as an overlooked dimension of research capacity strengthening: how to embed value-driven practices in global health](#) (4 January, 2024)

Candice Bonaconsa, Vrinda Nampootheri, Oluchi Mbamalu, Siphon Dlamini, Surya Surendran, Sanjeev K Singh, Raheelah Ahmad, Alison Holmes, Muneera A Rasheed, Marc Mendelson, Esmita Charani

Bulletin of the Atomic Scientists

November 2023

<https://thebulletin.org/magazine/2023-11/>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 102(1); 2024 Jan 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/451803/>

Editorial

[A digital transformation for primary health care](#)

Jarbas Barbosa da Silva, Marcos Espinal, Sebastian Garcia-Saiso, James Fitzgerald, Myrna Marti, Ernesto Bascolo, Ana Estela Haddad, Marcelo D'Agostino

Research

[Uptake of orphan drugs in the WHO essential medicines lists](#)

Enrico Costa, Lorenzo Moja, Veronika J Wirtz, Hendrika A van den Ham, Benedikt Huttner, Nicola Magrini, Hubert GM Leufkens

Bull World Health Organ. 2024 Jan 1; 102(1): 22–31. Published online 2023 Oct 31.

doi: 10.2471/BLT.23.289731

PMCID: PMC10753278

[Spatiotemporal trends in COVID-19 vaccine sentiments on a social media platform and correlations with reported vaccine coverage](#)

Xinyu Zhou, Xu Zhang, Heidi J Larson, Alexandre de Figueiredo, Mark Jit, Samah Fodeh, Sten H Vermund, Shujie Zang, Leesa Lin, Zhiyuan Hou

Bull World Health Organ. 2024 Jan 1; 102(1): 32–45. Published online 2023 Oct 31.

doi: 10.2471/BLT.23.289682

PMCID: PMC10753281

[Vaccinating humanitarian workers against COVID-19](#)

Anne-Gaelle Selod, Jaclyn Perhati, Cedric Dumont, Baptiste Danjou, Daniel Cook

Bull World Health Organ. 2024 Jan 1; 102(1): 46–57. Published online 2023 Nov 21.

doi: 10.2471/BLT.23.289980

PMCID: PMC10753276

Policy & Practice

[Reassessing potential economic value and health impact of effective Shigella vaccines](#)

William P Hausdorff, John D Anderson, IV, A Louis Bourgeois, Allison Clifford, Jessica A Fleming, Farzana Muhib, Clint Pecenka, Chloe Puett, Mark S Riddle, Suzanne Scheele, Karoun H Bagamian

Bull World Health Organ. 2024 Jan 1; 102(1): 65–74. Published online 2023 Dec 11.

doi: 10.2471/BLT.23.290163

PMCID: PMC10753284

Perspectives

[Advancing the “sexual” in sexual and reproductive health and rights: a global health, gender equality and human rights imperative](#)

Tedros Adhanom Ghebreyesus, Pascale Allotey, Manjulaa Narasimhan

Bull World Health Organ. 2024 Jan 1; 102(1): 77–78. Published online 2023 Dec 14.

doi: 10.2471/BLT.23.291227

PMCID: PMC10753275

Cell

Jan 04, 2024 Volume 187 Issue 1 p1-216

<https://www.cell.com/cell/current>

Commentaries

[The innovation menagerie: New institutional structures are expanding horizons for early-stage research](#)

Samuel G. Rodrigues

Academia is a vital source of innovation and discovery, but it faces challenges in funding and coordination. These challenges limit the scope and impact of academic research. Now, philanthropists and governments are exploring new institutional structures and funding strategies, with the goal of unleashing scientific discovery.

Child Care, Health and Development

Volume 49, Issue 6 Pages: 941-1111 November 2023

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 115, Issue 1 Pages: 1-157 January 2024

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

Research

Articles

[Practical and Statistical Considerations for the Long Term Follow-Up of Gene Therapy Trial Participants](#)

[Maximilian Rohde](#), [Seoan Huh](#), [Vanessa D'Souza](#), [Steven Arkin](#), [Erika Roberts](#), [Avery McIntosh](#)
avery.mcintosh@pfizer.com

Pages: 139-146 First Published: 27 October 2023

Abstract

Study sponsors and market authorization holders are required by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) to enroll patients administered a gene therapy product, whether in a trial setting or post-licensure, in a long term follow-up safety study to continue the safety assessments of their product. These follow-up studies range between 5 and 15 years after dosing. This unprecedented duration of engagement with patients and caregivers raises logistical challenges that will require innovation and collaboration across sponsors and regulators. In this paper we delineate some of the key considerations for designing long term follow-up protocols in the gene therapy setting, with an eye toward platform and master protocol approaches, and offer guidance for innovative operational and statistical methods that can help assess the safety profile and durability of response for these novel therapeutics.

Clinical Therapeutics

January 2024 Volume 46 Issue 1 p1-84

<http://www.clinicaltherapeutics.com/current>

[New issue; No digest content identified]

Clinical Trials

Volume 20 Issue 6, December 2023

<https://journals.sagepub.com/toc/ctja/20/6>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 06 Jan 2024]

[Health systems resilience in fragile and conflict-affected settings: a systematic scoping review](#)

Health systems resilience (HSR) research is a rapidly expanding field, in which key concepts are discussed and theoretical frameworks are emerging with vibrant debate. Fragile and conflict-affected settings (F...

Authors: Claudia Truppa, Sally Yaacoub, Martina Valente, Giulia Celentano, Luca Ragazzoni and Dell Saulnier

Citation: Conflict and Health 2024 18:2

Content type: Research Published on: 3 January 2024

Contemporary Clinical Trials

Volume 134 November 2023

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/134/suppl/C>

[Reviewed earlier]

The CRISPR Journal

Volume 6, Issue 6 / December 2023

<https://www.liebertpub.com/toc/crispr/6/6>

[New issue; No digest content identified]

Current Genetic Medicine Reports

Volume 11, issue 1-2, June 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-1>

[Reviewed earlier]

Current Medical Research and Opinion

Volume 40, Issue 1 2024

<https://www.tandfonline.com/toc/icmo20/current>

Vaccines

Article

[Awareness, attitudes, and practices on meningococcal serogroup B vaccination in the United States among parents of older adolescents and among young adults](#)

[Oscar Herrera-Restrepo](#), [Zifan Zhou](#), [Annie Krishnan](#), [Wanda J. Conley](#), [Eni Oladele](#), [Jasjit K. Multani](#), [Rifat Tuly](#), [Liucheng Shi](#), [Chi-Chang Chen](#), [Scott Preiss](#) & [Diana E. Clements](#)

Pages: 125-140

Published online: 03 Jan 2024

Study Design

[Statistical recommendations for the Global Burden of Disease studies](#)

[Michal Ordak](#)

Pages: 123-124

Published online: 03 Jan 2024

Studies Global Burden of Disease (GBD) presents an all-encompassing portrayal of mortality and disability, considering various countries, time periods, age groups, and sex. This article presents statistical recommendations for GBD studies.

Current Opinion in Infectious Diseases

February 2024 - Volume 37 - Issue 1

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

STD

[Promising developments in gonococcal vaccines](#)

Waltmann, Andreea; Chen, Jane S.; Duncan, Joseph A.
Current Opinion in Infectious Diseases. 37(1):63-69, February 2024.

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 06 Jan 2024]

[No new digest content identified]

Developing World Bioethics

Volume 23, Issue 4 Pages: 293-377 December 2023

<https://onlinelibrary.wiley.com/toc/14718847/current>

ORIGINAL ARTICLES

[Reviewed earlier]

Development in Practice

Volume 33, Issue 8, 2023

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

Development Policy Review

Volume 42, Issue 1 January 2024

<https://onlinelibrary.wiley.com/toc/14677679/current>

[New issue; No digest content identified]

Disaster Medicine and Public Health Preparedness

Volume 17 - 2024

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

Original Research

[Evaluation of Risk Perception of COVID-19 Disease: A Community-Based Participatory Study](#)

[Ezat Samadipour](#), [Fatemeh Ghardashi](#), [Nahid Aghaei](#)

Published online by Cambridge University Press:

02 September 2020, e10

Concepts in Disaster Medicine

[The Promise of Disease Detection Dogs in Pandemic Response: Lessons Learned From COVID-19](#)

[Cynthia M. Otto](#), [Tara Kirk Sell](#), [Tener Goodwin Veenema](#), [Divya Hosangadi](#), [Rachel A. Vahey](#), [Nancy D. Connell](#), [Lois Privor-Dumm](#)

Published online by Cambridge University Press:

08 June 2021, e20

Disasters

Volume 47, Issue 4 Pages: 847-1173 October 2023
<https://onlinelibrary.wiley.com/toc/14677717/2023/47/4>
[Reviewed earlier]

EMBO Reports

Volume 24 Issue 12 6 December 2023
<https://www.embopress.org/toc/14693178/current>
[Reviewed earlier]

Emerging Infectious Diseases

Volume 29, Number 12—December 2023
<http://wwwnc.cdc.gov/eid/>
[New issue; No digest content identified]

Epidemics

Volume 45 December 2023
<https://www.sciencedirect.com/journal/epidemics/vol/45/suppl/C>
[Reviewed earlier]

Epidemiology and Infection

Volume 152 - 2024
<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>
Original Research
[**Global, regional, and national disease burden and attributable risk factors of HIV/AIDS in older adults aged 70 years and above: a trend analysis based on the Global Burden of Disease study 2019**](#)
[Min Du, Min Liu, Jue Liu](#)
Published online by Cambridge University Press:
15 December 2023, e2

Ethics & Human Research

Volume 45, Issue 6 Pages: 1-50 November–December 2023
<https://onlinelibrary.wiley.com/toc/25782363/current>
Passing demands in autism research :: Women missing in phase I trials
[Reviewed earlier]

Ethics & International Affairs

Volume 37 - Issue 3 - Fall 2023
<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>
[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 31 (December 2023)
<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C>
[Reviewed earlier]

The European Journal of Public Health

Volume 33, Issue 6, December 2023

<https://academic.oup.com/eurpub/issue/33/6>

[Reviewed earlier]

Expert Review of Vaccines

Vol 22 (1) 2023

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

January/February 2024 Volume 103, Number 1

<https://www.foreignaffairs.com/issues/2023/103/1>

[Reviewed earlier]

Forum for Development Studies

Volume 50, 2023 - Issue 3

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Genetics in Medicines

Volume 26, Issue 1 January 2024

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/25/issue/12>

[New issue; No digest content identified]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 06 Jan 2024]

[Using multi-scale genomics to associate poorly annotated genes with rare diseases](#)

Next-generation sequencing (NGS) has significantly transformed the landscape of identifying disease-causing genes associated with genetic disorders. However, a substantial portion of sequenced patients remains...

Authors: Christina Canavati, Dana Sherill-Rofe, Lara Kamal, Idit Bloch, Fouad Zahdeh, Elad Sharon, Batel Terespolsky, Islam Abu Allan, Grace Rabie, Mariana Kawas, Hanin Kassem, Karen B. Avraham, Paul Renbaum, Ephrat Levy-Lahad, Moien Kanaan and Yuval Tabach

Citation: Genome Medicine 2024 16:4

Content type: Research Published on: 4 January 2024

Global Health Action

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/zgha20/current?nav=toCList>

Review Article

[The effectiveness of rural community health workers in improving health outcomes during the COVID-19 pandemic: a systematic review](#)

Neema Kaseje, Meghna Ranganathan, Monica Magadi, Kevin Oria & Andy Haines

Article: 2292385

Published online: 05 Jan 2024

Global Health: Science and Practice (GHSP)

Vol. 11, No. 6 December 22, 2023

<http://www.ghspjournal.org/content/current>

Original Articles

[Keeping the Customer Satisfied: Applying a Kano Model to Improve Vaccine Promotion in the Philippines](#)

Jonas Wachinger, Mark Donald C. Reñosa, Jerric Rhazel Guevarra, Jhoys Landicho-Guevarra, Maria Paz Demonteverde, Catherine Silvestre, Vivienne Endoma, Jeniffer Landicho, Mila F. Aligato, Thea Andrea Bravo, Rachel P. Chase and Shannon A. McMahon

Global Health: Science and Practice December 2023, 11(6):e2300199;

<https://doi.org/10.9745/GHSP-D-23-00199>

The authors show how global health science and practice can benefit from applying approaches established in other fields, such as consumer psychology and quality management, to increase clients' satisfaction with health interventions.

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 06 Jan 2024]

[No new digest content identified]

Global Public Health

Volume 19, Issue 1 (2024)

<http://www.tandfonline.com/toc/rgph20/current>

[New issue; No digest content identified]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 06 Jan 2024]

[No new digest content identified]

Health and Human Rights

Volume 25, Issue 2, December 2023

<https://www.hhrjournal.org/volume-25-issue-2-december-2023/>

Special Section: Economic Inequality and the Right to Health

Health Economics, Policy and Law

Volume 18 - Special Issue 4 - October 2023

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

SPECIAL ISSUE: On the roof top of health policy change

[Reviewed earlier]

Health Policy and Planning

Volume 38, Issue 10, December 2023

<https://academic.oup.com/heapol/issue/38/10>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 06 Jan 2024]

[A scoping review of the globally available tools for assessing health research partnership outcomes and impacts](#)

Health research partnership approaches have grown in popularity over the past decade, but the systematic evaluation of their outcomes and impacts has not kept equal pace. Identifying partnership assessment too...

Authors: Kelly J. Mrklas, Jamie M. Boyd, Sumair Shergill, Sera Merali, Masood Khan, Cheryl Moser, Lorelli Nowell, Amelia Goertzen, Liam Swain, Lisa M. Pfadenhauer, Kathryn M. Sibley, Mathew Vis-Dunbar, Michael D. Hill, Shelley Raffin-Bouchal, Marcello Tonelli and Ian D. Graham

Citation: Health Research Policy and Systems 2023 21:139

Content type: Review Published on: 22 December 2023

Human Gene Therapy

Volume 34, Issue 23-24 / December 2023

<https://www.liebertpub.com/toc/hum/34/23-24>

Reviews

[The Lived Experience of Pediatric Gene Therapy: A Scoping Review](#)

[Laura Kimberly](#), [Cara Hunt](#), [Katherine Beaverson](#), [Emma James](#), [Alison Bateman-House](#), [Richard McGowan](#), and [Jennifer DeSante-Bertkau](#)

Pages:1180–1189

Published Online:15 November 2023

<https://doi.org/10.1089/hum.2023.157>

Humanitarian Practice Network

<https://odihpn.org/>

Featured Publications

[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 19, Issue 3, 2023

<https://www.tandfonline.com/toc/khvi20/19/3?nav=tocList>

[Reviewed earlier]

Immunity

Dec 12, 2023 Volume 56 Issue 12 p2665-2856

<https://www.cell.com/immunity/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 06 Jan 2024]

[Willingness to accept human papilloma virus vaccination and its associated factors among parents with eligible daughters in Addis Zemen town, Northwest Ethiopia](#)

Authors: Mulugeta Wassie, Alebachew Ferede Zegeye, Wondesen Worku, Tiruye Sisay, Tsadik Eyob and Daniel Ayelegne Gebeyehu

Content type: Research 21 December 2023

Infectious Diseases of Poverty

<http://www.idpjournals.com/content>

[Accessed 06 Jan 2024]

[No new digest content identified]

International Health

Volume 15, Issue 6, November 2023

<https://academic.oup.com/inthealth/issue/15/6>

[Reviewed earlier]

International Human Rights Law Review

Volume 12 (2023): Issue 1 (Jul 2023)

<https://brill.com/view/journals/hrlr/12/1/hrlr.12.issue-1.xml>

Table of Contents

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 10 No. 9 (2023): September 2023

<https://www.ijcmph.com/index.php/ijcmph/issue/view/104>

[Reviewed earlier]

International Journal of Epidemiology

Volume 52, Issue 6, December 2023

<https://academic.oup.com/ije/issue>

[New issue; No digest content identified]

International Journal of Human Rights in Healthcare

Volume 16 Issue 3 2023

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/16/iss/3>

Table of contents

[Reviewed earlier]

JAMA

January 2, 2024, Vol 331, No. 1, Pages 7-86

<https://jamanetwork.com/journals/jama/currentissue>

Special Communication

AI in Medicine

[Will Generative Artificial Intelligence Deliver on Its Promise in Health Care?](#)

Robert M. Wachter, MD; Erik Brynjolfsson, PhD

JAMA. 2024;331(1):65-69. doi:10.1001/jama.2023.25054

Generative artificial intelligence (AI) has been touted as a potential innovation for greater diagnostic accuracy and clinical efficiency in health care, but whether generative AI will deliver on this promise or fall to the “productivity paradox” is examined in this Special Communication.

December 26, 2023, Vol 330, No. 24, Pages 2321-2404

<https://jamanetwork.com/journals/jama/issue/330/24>

[New issue; No digest content identified]

December 19, 2023, Vol 330, No. 23, Pages 2235-2314

<https://jamanetwork.com/journals/jama/issue/330/23>

Climate Change and Health

[Clinical Research Risks, Climate Change, and Human Health](#)

Jeff D'Souza, PhD; Gabrielle Samuel, PhD

JAMA. 2023;330(23):2247-2248. doi:10.1001/jama.2023.23724

This Viewpoint discusses ways in which clinical research directly and indirectly contributes to anthropogenic climate change, highlights the need for increased scientific soundness and value in research, and calls for the development of tools for calculating the environmental impact of studies and a strategy for ensuring that research does not compromise the rights and welfare of nonparticipants and future generations.

Editor's Note

[Climate Change and Health—A New JAMA Series](#)

Mary M. McDermott, MD; Kirsten Bibbins-Domingo, PhD, MD, MAS

JAMA Health Forum

January 2024, Vol 5, No. 1

<https://jamanetwork.com/journals/jama-health-forum/issue>

[New issue; No digest content identified]

JAMA Pediatrics

January 2024, Vol 5, No. 1

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

Editorial

[What Health Systems Can Do Now to Improve Human Papillomavirus Vaccination](#)

Mary Kate Kelly, MPH; Rachel A. Katzenellenbogen, MD; Alexander G. Fiks, MD, MSCE

JAMA Pediatr. 2024;178(1):13-14. doi:10.1001/jamapediatrics.2023.5070

Original Investigation

[Multilevel Implementation Strategies for Adolescent Human Papillomavirus Vaccine UptakeA Cluster Randomized Clinical Trial](#)

Lila J. Finney Rutten, PhD; Joan M. Griffin, PhD; Jennifer L. St. Sauver, PhD; et al.

JAMA Pediatr. 2024;178(1):29-36. doi:10.1001/jamapediatrics.2023.4932

This study evaluates the individual and combined impact of 2 evidence-based interventions on human papillomavirus vaccination rates among 11- and 12-year-old children.

JBI Evidence Synthesis

December 2023 - Volume 21 - Issue 12

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[New issue; No digest content identified]

Journal of Adolescent Health

January 2024 Volume 74 Issue 1 p1-212

<https://www.jahonline.org/current>

Original Articles

[A Multivariate Probit Regression of the Uptake of Adolescent Vaccines Among Racial/Ethnic Minority Adolescents Before and During the COVID-19 Pandemic](#)

Chinenye Lynette Ejezie, et al.

Published online: October 07, 2023

p28-35

Journal of Artificial Intelligence Research

Vol. 78 (2023)

<https://www.jair.org/index.php/jair>

Contents

[Reviewed earlier]

Journal of Community Health

Volume 48, issue 6, December 2023

<https://link.springer.com/journal/10900/volumes-and-issues/48-6>

[Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 7 No. 01 (2024), January 2, 2024 , Page 1988-1996

<https://www.cmro.in/index.php/jcmro/issue/view/75>

[New issue; No digest content identified]

Journal of Development Economics

Volume 166 January 2024

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/166/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 18 Issue 5, December 2023

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

January 2024 - Volume 78 - 1

<https://jech.bmj.com/content/78/1>

[New issue; No digest content identified]

Journal of Evidence-Based Medicine

Volume 16, Issue 4 Pages: 415-580 December 2023

<https://onlinelibrary.wiley.com/toc/17565391/current>

[New issue; No digest content identified]

Journal of Global Ethics

Volume 19, Issue 2 (2023)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 34, Number 4, November 2023

<https://muse.jhu.edu/issue/51329>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 25, issue 6, December 2023

<https://link.springer.com/journal/10903/volumes-and-issues/25-6>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 21, 2023 _ Issue 4

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of Infectious Diseases

Volume 228, Issue 12, 15 December 2023

<https://academic.oup.com/jid/issue/228/12>

[New issue; No digest content identified]

Journal of International Development

Volume 35, Issue 8 Pages: 2251-2685 November 2023

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Medical Ethics

December 2023 - Volume 49 - 12

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 10, Issue 3 (2023)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

The Journal of Pediatrics

Volume 264 January 2024

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/264/suppl/C>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

<https://joppp.biomedcentral.com/>

[Accessed 06 Jan 2024]

[Pharmacist-led vaccination services in the Middle East](#)

Successful Vaccine uptake relies heavily on the effectiveness of vaccination services. Expanding the scope of pharmacists' involvement in vaccination services can significantly improve vaccination coverage. Th...

Authors: Faten Naif Aldajani and Mohammed Aldosari

Citation: Journal of Pharmaceutical Policy and Practice 2023 16:171

Content type: Review Published on: 29 December 2023

Journal of Public Health Management & Practice

January/February 2024 - Volume 30 - Issue 1

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 44, issue 4, December 2023

<https://link.springer.com/journal/41271/volumes-and-issues/44-4>

[New issue; No digest content identified]

Journal of the Royal Society – Interface

January 2024 Volume 21 Issue 210

<https://royalsocietypublishing.org/toc/rsif/current>

Life Sciences–Physics interface

Research articles

[Temporal clustering of social interactions trades-off disease spreading and knowledge diffusion](#)

[Giulia Cencetti](#), [Lorenzo Lucchini](#), [Gabriele Santin](#), [Federico Battiston](#), [Esteban Moro](#), [Alex Pentland](#) and [Bruno Lepri](#)

Published:03 January 2024Article ID:20230471

Abstract

Non-pharmaceutical measures such as preventive quarantines, remote working, school and workplace closures, lockdowns, etc. have shown effectiveness from an epidemic control perspective;

however, they have also significant negative consequences on social life and relationships, work routines and community engagement. In particular, complex ideas, work and school collaborations, innovative discoveries and resilient norms formation and maintenance, which often require face-to-face interactions of two or more parties to be developed and synergically coordinated, are particularly affected. In this study, we propose an alternative hybrid solution that balances the slowdown of epidemic diffusion with the preservation of face-to-face interactions, that we test simulating a disease and a knowledge spreading simultaneously on a network of contacts. Our approach involves a two-step partitioning of the population. First, we tune the level of node clustering, creating 'social bubbles' with increased contacts within each bubble and fewer outside, while maintaining the average number of contacts in each network. Second, we tune the level of temporal clustering by pairing, for a certain time interval, nodes from specific social bubbles. Our results demonstrate that a hybrid approach can achieve better trade-offs between epidemic control and complex knowledge diffusion. The versatility of our model enables tuning and refining clustering levels to optimally achieve the desired trade-off, based on the potentially changing characteristics of a disease or knowledge diffusion process.

Journal of Travel Medicine

Volume 30, Issue 8, December 2023

<https://academic.oup.com/jtm/issue>

Editorials

[Dengue severity in travellers: challenges and insights](#)

Sarah L McGuinness and Karin Leder

Editor's Choice

[R21/Matrix-M™ malaria vaccine: a new tool to achieve WHO's goal to eliminate malaria in 30 countries by 2030?](#)

Blaise Genton

A potential breakthrough in the fight against malaria is the availability of a new promising tool, the R21/Matrix-M™ malaria vaccine that has shown an efficacy of 75% to protect young children against clinical malaria in different epidemiological settings. WHO recommends its deployment in addition to RTS,S/AS01 and other effective interventions.

Systematic Reviews

[Interventions to increase vaccination against COVID-19, influenza and pertussis during pregnancy: a systematic review and meta-analysis](#)

Mohammad S Razai and others

Journal of Virology

Volume 97 • Number 12 • December 2023

<http://jvi.asm.org/content/current>

[New issue; No digest content identified]

The Lancet

Jan 06, 2024 Volume 403 Number 10421 p1-116, e1

<https://www.thelancet.com/journals/lancet/issue/current>

Comment

[Tackling health emergencies in complex settings: the role of national public health institutes in the Eastern Mediterranean region](#)

Wasiq Khan...

Richard Brennan

The UN High-Level Meeting in September, 2023, concluded with the approval of a Declaration on pandemic prevention that received mixed reaction from the stakeholders. [1,2](#) The Declaration calls for an encompassing approach to emergency preparedness and response (EPR) and for empowering national systems and strengthening coordination and leadership. [3](#) In complex settings such as several countries in WHO's Eastern Mediterranean region, conflict, social and political instability, multiple disease outbreaks, insufficiently resourced health systems, and large-scale health and social inequities [4](#) further confirm the need to adopt holistic approaches towards health emergencies management.

The Lancet Commissions

[**Pathways to a healthy net-zero future: report of the Lancet Pathfinder Commission**](#)

Sarah Whitmee, et al.

Lecture

[**Success from the South: the rotavirus vaccine story and its lessons**](#)

Gagandeep Kang

The Lancet Child & Adolescent Health

Jan 2024 Volume 8 Number 1 p1-84

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Dec 2023 Volume 5 Number 12 e848-e932

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Jan 2024 Volume 12 Number 1 e1-e169

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Jan 2024 Volume 24 Number 1 p1-106, e1-e69

<https://www.thelancet.com/journals/laninf/issue/current>

Editorial

[**A blueprint for elimination of cervical cancer**](#)

The Lancet Infectious Diseases

[Excerpt]

...Disadvantaged girls and women, especially those in LMICs and marginalised groups, are still disproportionately affected by cervical cancer. Although HPV vaccines have been available for almost two decades, access to the vaccines has not been equal and coverage of two doses has been low, in part due to vaccine hesitancy. Progress on screening and treatment is lagging. Many countries do not offer cervical cancer screening, and most countries with official recommendations for cervical cancer screening begin to screen women at age 30 years, repeating every 5 years, with the potential for delayed detection of early, treatable stages of cervical cancer. Tedros said that access to surgery, radiotherapy, chemotherapy, and palliative care needs to be better in most countries.

There is hope that the situation will improve. Recommendations supporting single-dose strategies for HPV immunisation make incorporating HPV vaccines into routine immunisation programmes a more realistic option for many countries and mean that many more girls can be protected. Nigeria, for instance, is aiming to reach 7.7 million girls with a single dose of HPV vaccine after introducing the vaccine into its immunisation programme in October, 2023. Production of HPV vaccines in LMICs—perhaps leveraging new vaccine manufacturing capacity in these countries in the wake of the COVID-19 pandemic—should ensure more equitable access to the vaccines. The Serum Institute of India, for example, is producing the country's first domestic HPV vaccine, Cervavax, after its approval on the basis of immunological data. This pathway to licensure, made possible by the established efficacy of existing vaccines, is less costly and time-consuming than the traditional route of demonstrating efficacy against disease in large trials and could expedite approval of other HPV vaccines in development...

Articles

[Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial](#)

Bruno Maranda, et al on behalf of the IBIO-INH-001 Investigators

[Mpox in people with past infection or a complete vaccination course: a global case series](#)

Aniruddha Hazra, et al. on behalf of SHARE-NET writing group

Personal View

[Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients](#)

Benjamin W Teh, et al.

Lancet Public Health

Dec 2023 Volume 8 Number 12 e905-e1042

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

Lancet Respiratory Medicine

Jan 2024 Volume 12 Number 1 p1-88

<https://www.thelancet.com/journals/lanres/issue/current>

Editorial

[Patterns of respiratory infections after COVID-19](#)

The Lancet Respiratory Medicine

[Excerpt]

... Respiratory illnesses have re-emerged in unpredictable patterns after the pandemic, whereas COVID-19 cases seem to have reached a plateau in the USA. Scientists are unsure whether COVID-19 will become a winter virus since there appears to be no clear pattern yet, but capacities that were increased during COVID-19 need to be sustained for other infectious diseases. Population-level immunity following vaccination and infection wanes over time, and vaccine hesitancy remains a large problem that requires a targeted response. Better mathematical models to track the patterns of infectious disease and improved understanding of factors driving these changes could help to improve surveillance programmes and disease control efforts, as well as shape the response to future pandemic threats.

Maternal and Child Health Journal

Volume 27, issue 12, December 2023

<https://link.springer.com/journal/10995/volumes-and-issues/27-12>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 101, Issue 4 Pages: 999-1374 December 2023

<http://mdm.sagepub.com/content/current>

[New issue; No digest content identified]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 101, Issue 3 Pages: 637-998 September 2023

<https://onlinelibrary.wiley.com/toc/14680009/current>

Perspectives

[Advancing Dialogue About Consent and Molecular HIV Surveillance in the United States: Four Proposals Following a Federal Advisory Panel's Call for Major Reforms](#)

STEPHEN MOLLDRUM, ANTHONY K J SMITH, ALEXANDER McCLELLAND

Pages: 1033-1046

First Published: 28 June 2023

Molecular Therapy

Jan 03, 2024 Volume 32 Issue 1 p1-260

<https://www.cell.com/molecular-therapy/current>

Editorials

[First in vivo base-editing trial shows promise](#)

Renzhi Han

Since the first report of CRISPR-Cas9 gene editing in human cells in 2013,^{1,2} CRISPR genome editing has emerged as an exciting therapeutic platform for numerous human diseases. The approval of the world's first CRISPR-Cas9 gene editing therapy, CASGEVY, by the UK's regulator on November 16, 2023 and the US Food and Drug Administration (FDA) on December 8, 2023, was a historic milestone. CASGEVY is developed by Vertex Pharmaceuticals and CRISPR Therapeutics for the treatment of sickle cell disease and β -thalassemia.

[Gene and cell therapy in 2023: Rich pipeline, slimming resources?](#)

Katherine A. High

Gene therapy, including both in vivo gene transfer and therapy with gene-modified cells, has moved in recent years from the realm of investigation to marketed products and is now one of the fastest growing classes of therapeutics. Two articles recently published in Molecular Therapy seek to provide a view of ongoing and recent activities in the space.^{1,2} Though they use different methodologies and indeed begin from altogether different definitions of gene therapy, they reach some of the same conclusions or at least have similar implications.

Nature

Volume 625 Issue 7993, 4 January 2024

<https://www.nature.com/nature/volumes/622/issues/7993>

Editorial 03 Jan 2024

[A new class of antibiotics is cause for cautious celebration — but the economics must be fixed](#)

The threat of antimicrobial resistance means that new antibiotics need to be used sparingly. Governments must support their development with a long-term funding plan.

Perspective 13 Dec 2023

[Hold out the genome: a roadmap to solving the cis-regulatory code](#)

A roadmap towards solving the cis-regulatory code using a combination of machine learning and massively parallel assays of exogenous DNA is proposed.

Carl G. de Boer, Jussi Taipale

Volume 624 Issue 7992, 21 December 2023

<https://www.nature.com/nature/volumes/624/issues/7992>

Editorial 20 Dec 2023

[End the glaring inequity in international science collaborations](#)

The world's natural-science research ecosystem remains focused on the priorities of high-income countries. Funders, publishers and scholarly databases can do more to help to rebalance that.

Editorial 19 Dec 2023

[From Einstein to AI: how 100 years have shaped science](#)

Looking back a century reveals how much the research landscape has changed — and how unclear the consequences of scientific innovation can be.

Nature Biotechnology

Volume 41 Issue 12, December 2023

<https://www.nature.com/nbt/volumes/41/issues/12>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 06 Jan 2024)

[No new digest content identified]

Nature Genetics

Volume 55 Issue 12, December 2023

<https://www.nature.com/ng/volumes/55/issues/12>

[Reviewed earlier]

Nature Human Behaviour

Volume 7 Issue 12, December 2023

<https://www.nature.com/nathumbehav/volumes/7/issues/12>

Moral reasoning in the brain

Moral foundations theory posits that there are five or six universal groups of moral intuitions (that is, 'foundations'), each of which is served by functionally specialized, dissociable cognitive mechanisms. Hopp et al. probe the neural (dis)unity of moral foundations theory and report that each moral foundation recruits domain-general mechanisms of social cognition, but also has a dissociable neural signature that is malleable by sociomoral experience.

Article 07 Sept 2023

[Moral foundations elicit shared and dissociable cortical activation modulated by political ideology](#)

Hopp et al. probe the neural (dis)unity of moral foundations theory and report that each moral foundation recruits domain-general mechanisms of social cognition but also has a dissociable neural signature malleable by sociomoral experience.

Frederic R. Hopp, Ori Amir, René Weber

Nature Medicine

Volume 29 Issue 12, December 2023

<https://www.nature.com/nm/volumes/29/issues/12>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 22 Issue 11, November 2023

<https://www.nature.com/nrd/volumes/22/issues/11>

Comment 23 Oct 2023

[IRDIRC Drug Repurposing Guidebook: making better use of existing drugs to tackle rare diseases](#)

The International Rare Diseases Research Consortium (IRDIRC) has developed a new guidebook to invigorate drug repurposing for rare diseases.

Anneliene Hechtelt Jonker, Simon Day, Anna Maria Gerdina Pasmooij

Nature Reviews Genetics

Volume 25 Issue 1, January 2024

<https://www.nature.com/nrg/volumes/25/issues/1>

Comment 22 Nov 2023

[Weaponized genomics: potential threats to international and human security](#)

Geopolitical instability has prompted renewed discussions on the risks of DNA technology being weaponized in international conflict. With today's changing security environment, the authors argue that risk assessments must be broadened from genetically targeted weapons to a series of new domains.

Subhayan Chattopadhyay, Tony Ingesson, David Gisselsson

Review Article 24 Aug 2023

[Principles and methods for transferring polygenic risk scores across global populations](#)

This Review summarizes the genetic and non-genetic factors that impact the transferability of polygenic risk scores (PRSs) across populations, highlighting the technical challenges of existing PRS construction methods for diverse ancestries and the emerging resources for more widespread use of PRSs.

Linda Kachuri, Nilanjan Chatterjee, Tian Ge

Review Article 04 Sept 2023

[Harnessing deep learning for population genetic inference](#)

Applying deep learning to large-scale genomic data of species or populations is providing new opportunities to understand the evolutionary forces that drive genetic diversity. This Review introduces common deep learning architectures and provides comprehensive guidelines to implement deep learning models for population genetic inference. The authors also discuss current opportunities and challenges for deep learning in population genetics.

Xin Huang, Aigerim Rymbekova, Martin Kuhlwilm

Nature Reviews Immunology

Volume 23 Issue 12, December 2023

<https://www.nature.com/nri/volumes/23/issues/12>

World View 16 Nov 2023

[Communicating science effectively in times of crisis: time for reflection](#)

Gary Koretzky, who was president of the American Association of Immunologists from 2021 to 2022, shares his thoughts on the responsibility of scientists to make science more accessible to a broad public, and reflects on lessons learned during the pandemic.

Gary Koretzky

New England Journal of Medicine

January 4, 2024 Vol. 390 No. 1

<https://www.nejm.org/toc/nejm/medical-journal>

[New issue; No digest content identified]

December 28, 2023 Vol. 389 No. 26

<https://www.nejm.org/toc/nejm/389/26>

Perspective

[Interactive Perspective: Health Care on the Edge — Challenges of Refugee Medicine](#)

[P. Calderon Vargas and Others](#)

Editorials

[RSV Prevention — Breakthroughs and Challenges](#)

[N.B. Halasa](#)

December 21, 2023 Vol. 389 No. 25

<https://www.nejm.org/toc/nejm/389/25>

Perspective

[Fundamentals of Medical Ethics: Deciding for Patients Who Have Lost Decision-Making Capacity — Finding Common Ground in Medical Ethics](#)

B. Lo

Editorials

[Fundamentals of Medical Ethics — A New Perspective Series](#)

B. Lo, D. Malina, G. Pittman, and S. Morrissey

njp Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 06 Jan 2024]

[No new digest content identified]

Pediatrics

Volume 153, Issue 1 January 2024

<https://publications.aap.org/pediatrics/issue/152/4>

Articles

[Invasive Pneumococcal Disease After 2 Decades of Pneumococcal Conjugate Vaccine Use](#)

[Inci Yildirim, MD, PhD](#); [Rotem Lapidot, MD](#); [Yazdani Basha Shaik-Dasthagirisaheb, BA](#); [Sarah Hinderstein, BA](#); [Hanna Lee, MD](#)

PharmacoEconomics

Volume 41, Issue 12 December 2023

<https://link.springer.com/journal/40273/volumes-and-issues/41-12>

Scoping Review

[Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies](#)

Deborah A. Marshall, Brittany Gerber, Gillian R. Currie

18 August 2023 Pages: 1563 - 1588

Rare diseases have a significant impact on patients, families, the health system, and society. Measuring the socioeconomic burden is crucial to valuing interventions for rare diseases. Healthcare system costs are significant, but so are costs to other government sectors, patients, families, and society. To understand the breadth of costs captured in rare disease studies, we examined the cost categories and elements of socioeconomic burden captured in published studies.

Conclusions

Contrary to cost-of-illness analyses, most of the included economic evaluations did not account for the hidden burden of rare diseases, that is, costs borne by patients, families, and societies. Including these types of costs in future studies would provide a more comprehensive picture of the burden of disease, providing empirical data to inform how we value and make decisions regarding rare disease interventions, health policy, and resource allocation.

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 06 Jan 2024)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 06 Jan 2024)

[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOGlobalPublicHealth&q=&resultsPerPage=60

(Accessed 06 Jan 2024)

[Mechanism design for a fair and equitable approach to global vaccine distribution: The case of COVID-19](#)

Khaled Abedrabboh, Lolwa Al-Majid, Zaid Al-Fagih, Luluwah Al-Fagih

Research Article | published 28 Dec 2023 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0001711>

[Developing a diversity, equity and inclusion compass to guide scientific capacity strengthening efforts in Africa](#)

Victoria O. Kasprowicz, Kim Darley Waddilove, Denis Chopera, Siphon Khumalo, Sashin Harilall, Emily B. Wong, Etienne Karita, Eduard J. Sanders, William Kilembe, Simani Gaseitsiwe, Thumbi Ndung'u
Research Article | published 20 Dec 2023 PLOS Global Public Health
<https://doi.org/10.1371/journal.pgph.0002339>

[Public perceptions of Ebola vaccines and confidence in health services to treat Ebola, malaria, and tuberculosis: Findings from a cross-sectional household survey in Uganda, 2020](#)

Aybüke Koyuncu, Rosalind J. Carter, Joseph Musaazi, Apophia Namageyo-Funa, Victoria M. Carter, Mohammed Lamorde, Dimitri Prybylski, Rose Apondi, Tabley Bakayaita, Amy L. Boore, Jaco Homsy, Vance R. Brown, Joanita Kigozi, Maria Sarah Nabaggala, Vivian Nakate, Emmanuel Nkurunziza, Daniel F. Stowell, Richard Walwema, Apollo Olowo, Mohamed F. Jalloh
Research Article | published 19 Dec 2023 PLOS Global Public Health
<https://doi.org/10.1371/journal.pgph.0001884>

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 06 Jan 2024)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 06 Jan 2024)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 06 Jan 2024]

[COVID-19 vaccine hesitancy among healthcare workers in Arab Countries: A systematic review and meta-analysis](#)

Mai Alalawi, Muath A. Alsalloum, Yusuf M. Garwan, Mya Abuzeid, Hassan Alalawi, Khalid Eljaaly, Abrar K. Thabit, Jimmy Jose

Research Article | published 02 Jan 2024 PLOS ONE

<https://doi.org/10.1371/journal.pone.0296432>

[Participants' understanding of informed consent in clinical trials: A systematic review and updated meta-analysis](#)

Chengai Wu, Na Wang, Qianqian Wang, Chao Wang, Zhenjie Wei, Zhimin Wu, Shunan Yu, Xieyuan Jiang

Research Article | published 02 Jan 2024 PLOS ONE

<https://doi.org/10.1371/journal.pone.0295784>

[COVID-19 in Pakistan: A national analysis of five pandemic waves](#)

Taimoor Ahmad, Mujahid Abdullah, Abdul Mueed, Faisal Sultan, Ayesha Khan, Adnan Ahmad Khan

Research Article | published 29 Dec 2023 PLOS ONE

<https://doi.org/10.1371/journal.pone.0281326>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 06 Jan 2024]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

January 9, 2024 | vol. 121 | no. 2

<https://www.pnas.org/toc/pnas/121/2>

[New issue; No digest content identified]

PNAS Nexus

Volume 2, Issue 12, December 2023

<https://academic.oup.com/pnasnexus/issue/2/12>

Editorial

[Advancing health through artificial intelligence/machine learning: The critical importance of multidisciplinary collaboration](#)

Monica M Bertagnolli

[Achieving the promise of artificial intelligence in health and medicine: Building a foundation for the future](#)

Victor J Dzau and others

... As Monica Bertagnolli, newly confirmed director of the National Institutes of Health, points out in this issue of PNAS Nexus (1)—“While the potential for AI/ML applications to improve human health research is vast, there are key challenges that must be overcome in order to optimize the outcome for the patient.” At the federal level, there is increasing recognition of the need to ensure AI/ML implementation is responsible, ethical, and equitable, maximizing benefits while minimizing the potential for harm to society. President Biden's recent Executive Order on the Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence (2) establishes first-of-its-kind standards in the United States for safety, privacy, and civil rights, while still emphasizing the need for scientific innovation and advancement. As Bertagnolli rightfully points out, a multidisciplinary perspective is required to achieve these important goals—one that is inclusive of not only researchers and clinicians but also patients and community organizations, social scientists and equity researchers, and policy and legal experts.

Brief Report

[Distance to vaccine sites is tied to decreased COVID-19 vaccine uptake](#)

Asaf Mazar and others

Prehospital & Disaster Medicine

Volume 38 - Issue 6 - December 2023

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[New issue; No digest content identified]

Preventive Medicine

Volume 178 January 2024

<https://www.sciencedirect.com/journal/preventive-medicine/vol/178/suppl/C>

Research article Open access

[Evaluating the cost-effectiveness of HPV vaccination for adolescent girls in Japan: A comparison of 2-valent, 4-valent, and 9-valent HPV vaccines with consideration of cross-protection](#)

Wongyeong Choi, Eunha Shim
Article 107743

Proceedings of the Royal Society B

10 January 2024 Volume 291 Issue 2014
<https://royalsocietypublishing.org/toc/rspb/current>
[New issue; No digest content identified]

Public Health

Volume 225 Pages e1-e4, 1-376 (December 2023)
<https://www.sciencedirect.com/journal/public-health/vol/225/suppl/C>

Research article Open access

[Lessons learnt from the COVID-19 pandemic in selected countries to inform strengthening of public health systems: a qualitative study](#)

K. Cardwell, B. Clyne, N. Broderick, B. Tyner, ... M. O'Neill
Pages 343-352

Special Section on Disease Surveillance & Response

Research article Open access

[The state of integrated disease surveillance in seven countries: a synthesis report](#)

A.C.K. Lee, B.G. Iversen, S. Lynes, A. Rahman-Shepherd, ... T. Pyone
Pages 141-146

Review article Abstract only

[Approaches, challenges, and opportunities to strengthen the epidemic intelligence workforce: a scoping review](#)

C.I. Gotsche, A. Meierkord, J. Baruch, L. Körner-Nahodilová, ... J. Hanefeld
Pages 353-359

Public Health Ethics

Volume 16, Issue 2, July 2023
<http://phe.oxfordjournals.org/content/current>
[Reviewed earlier]

Public Health Genomics

2023, Vol. 26, No. 1
<https://karger.com/phg/issue/26/1>
[Reviewed earlier]

Public Health Reports

Volume 139 Issue 1, January/February 2024
<https://journals.sagepub.com/toc/phrg/139/1>
Research article First published November 4, 2023pp. 102–111

[COVID-19 Vaccine Hesitancy Among US Adults: Safety and Effectiveness Perceptions and Messaging to Increase Vaccine Confidence and Intent to Vaccinate](#)

Nicole Weinstein MSW, et al.

Qualitative Health Research

Volume 34 Issue 3, February 2024

<https://journals.sagepub.com/toc/QHR/current>

[New issue; No digest content identified]

Research Ethics

Volume 19 Issue 4, October 2023

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 06 Jan 2024]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

18 Dec 2023

[Evaluating elimination of mother-to-child transmission of HIV in Suriname: a mixed method study](#)

Original research | English |

Risk Analysis

Volume 44, Issue 1 Pages: 1-280 January 2024

<https://onlinelibrary.wiley.com/toc/15396924/current>

ORIGINAL ARTICLES

[Political ideology shapes risk and benefit judgments of COVID-19 vaccines](#)

Enrico Rubaltelli, Stephan Dickert, David M. Markowitz, Paul Slovic

Pages: 126-140

First Published: 26 April 2023

[A classification system for characterizing the integrity and quality of evidence in risk studies](#)

Shital Thekdi, Terje Aven

Pages: 264-280

First Published: 27 April 2023

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 06 Jan 2024]

Original Research

Campaign Governance and Partnerships: Unraveling COVID-19 Vaccine Promotion Efforts in China's Neighborhoods

Yang R, Sun S

Risk Management and Healthcare Policy 2023, 16:2915-2929

Published Date: 28 December 2023

Science

Volume 383| Issue 6678| 5 Jan 2024

<https://www.science.org/toc/science/current>

Policy Forum

Biodiversity monitoring for a just planetary future

BY Melissa Chapman, et al.

04 Jan 2024: 34-36

Data that influence policy and major investment decisions risk entrenching social and political inequities

Volume 382| Issue 6677| 22 Dec 2023

<https://www.science.org/toc/science/382/6677>

[New issue; No digest content identified]

Science and Engineering Ethics

Volume 29, Issue 6 December 2023

<https://link.springer.com/journal/11948/volumes-and-issues/29-6>

[Reviewed earlier]

Science Translational Medicine

Volume 16| Issue 728| 3 Jan 2024

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 06 Jan 2024]

[No new digest content identified]

Social Science & Medicine

Volume 339 December 2023

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/339/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 06 Jan 2024]

Factors influencing HPV vaccine implementation in South Asia: a scoping review protocol

The HPV vaccine is characterized by its significant effectiveness in preventing the occurrence of cervical cancer. However, the South Asian countries face multiple challenges in implementing the human papillom...

Authors: Priyobrat Rajkhowa, Prachi Pundir, Sherize Merlin Dsouza, Divya Sussana Patil, Prakash Narayanan and Helmut Brand

Citation: Systematic Reviews 2024 13:14

Content type: Protocol Published on: 5 January 2024

Theoretical Medicine and Bioethics

Volume 44, Issue 6 December 2023

<https://link.springer.com/journal/11017/volumes-and-issues/44-6>

[New issue; No digest content identified]

Travel Medicine and Infectious Diseases

Volume 56 November–December 2023

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/56/suppl/C>

Editorial Open access

[SARS-CoV-2 vaccination strategies: Should the extended dosing interval strategy be implemented in future pandemics?](#)

Sandra Valderrama-Beltrán, Juliana Cuervo-Rojas, Samuel Martinez-Vernaza, Carlos A. Alvarez-Moreno, Alfonso J. Rodriguez-Morales

Article 102650

Research article Open access

[Mortality from COVID-19 in Amazonian and Andean original indigenous populations of Peru](#)

Agueda Muñoz-del-Carpio-Toia, Marco Bartolo-Marchena, Vicente A. Benites-Zapata, Percy Herrera-Añazco

Article 102658

Tropical Medicine & International Health

Volume 29, Issue 1 Pages: i-iv, 1-71 January 2024

<https://onlinelibrary.wiley.com/toc/13653156/current>

[New issue; No digest content identified]

Vaccine

Volume 42, Issue 2 Pages 65-402 (12 January 2024)

<https://www.sciencedirect.com/journal/vaccine/vol/42/issue/2>

Review article Abstract only

[Parental perceptions of chickenpox and the varicella vaccine: A qualitative systematic review](#)

Zoe Jordan, Emma Rowland

Pages 75-83

Review article Abstract only

[Relationship between vaccine hesitancy and vaccination behaviors: Systematic review and meta-analysis of observational studies](#)

Xuying Yang, Naiyang Shi, Chang Liu, Jiarong Zhang, ... Hui Jin

Pages 99-110

Research article Abstract only

[Effectiveness of COVID-19 vaccine mandates in raising vaccination rates among the elderly and general population in Europe: Controlled interrupted time series analysis](#)

Theodore Lytras, Abba Adema Alumasa Di Gregorio, Dimitrios Apostolopoulos, Demetris Naziris, ... Alexandros Heraclides

Pages 156-161

Research article Abstract only

[Impact of the COVID-19 pandemic on routine vaccination coverage under varying prevalence Conditions: A cohort study in Beijing, China](#)

Zhiqiang Cao, Rui Yu, Qianli Yuan, Wenyan Ji, ... Luodan Suo

Pages 213-219

Research article Open access

[Pneumococcal vaccination coverage and vaccination-related factors among older adults in Japan: LIFE Study](#)

Naoki Yamada, Kiyomasa Nakatsuka, Masato Tezuka, Fumiko Murata, ... Rei Ono

Pages 239-245

Research article Abstract only

[Effectiveness of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children <2 years old: A prospective population-based study in rural Bangladesh](#)

Roly Malaker, Md Hasanuzzaman, Yogesh Hooda, Hafizur Rahman, ... Samir K. Saha

Pages 255-262

Research article Abstract only

[Why did Brazil fail to vaccinate children against COVID-19 during the pandemic? An assessment of attitudinal and behavioral determinants](#)

Wladimir Gramacho, Mathieu Turgeon, Pedro Santos Mundim, Isadora Pereira

Pages 315-321

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 06 Jan 2024]

Latest Articles [Selected]

Open Access Systematic Review

[Worldwide Child Routine Vaccination Hesitancy Rate among Parents of Children Aged 0–6 Years: A Systematic Review and Meta-Analysis of Cross-Sectional Studies](#)

Vaccines 2024, 12(1), 31; <https://doi.org/10.3390/vaccines12010031> - 27 Dec 2023

Abstract

Routine vaccine hesitancy is a major global health challenge observed in over 190 countries worldwide. This meta-analysis aims to determine the worldwide prevalence of routine vaccination hesitancy among parents of children aged 0–6. An extensive search was conducted in four scientific databases...

Value in Health

December 2023 Volume 26 Issue 12 p1675-1812

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

World Development

Volume 175 March 2024

<https://www.sciencedirect.com/journal/world-development/vol/175/suppl/C>

Research article Open access

[Socioeconomic conditions and contagion dynamics of the COVID-19 pandemic with and without mitigation measures: Evidence from 185 countries](#)

Giorgos Galanis, Andreas Georgiadis

Article 106477

Research article Open access

[Short- and long-term food insecurity and policy responses in pandemics: Panel data evidence from COVID-19 in low- and middle-income countries](#)

Peter Hangoma, Kusum Hachhethu, Silvia Passeri, Ole Frithjof Norheim, ... Ottar Mæstad

Article 106479

.....

.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

.....

Pre-Print Servers

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 06 Jan 2024]

Selected Research

[No new digest content identified]

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 06 Jan 2024]

[Filter: All articles]

[The Struggle to Vaccinate: Unveiling the Reality of the first year of Covid-19 Vaccination in the Democratic Republic of Congo](#)

Adidja Amani, Aime Cikomola Mwana Bene, Christophe Luhata Lungoyo, Arsene Kabwaya Mukoka, Fabrice Zobel Lekeumo Cheuyem, Samuel Mpinganjira, Dumisile Sibongile Nkosi, Kimberly Cheryl Chido Konono, Michael Ngigi, Pierre Ongolo-Zogo

medRxiv 2024.01.03.24300795; doi: <https://doi.org/10.1101/2024.01.03.24300795>

[Measuring progress on health and well-being in the Eastern Mediterranean Region via voluntary national reviews, 2016 - 2021: what does the data reveal?](#)

RM Mabry, HV Doctor, MN Khair, M Abdelgalil, A Rashidian
medRxiv 2024.01.02.24300730; doi: <https://doi.org/10.1101/2024.01.02.24300730>

[Global risk of selection and spread of Plasmodium falciparum histidine-rich protein 2 and 3 gene deletions](#)

Oliver J. Watson, Thu Nguyen-Anh Tran, Robert J Zupko, Tasmin Symons, Rebecca Thomson, Theodoor Visser, Susan Rumisha, Paulina A Dzianach, Nicholas Hathaway, Isaac Kim, Jonathan J. Juliano, Jeffrey A. Bailey, Hannah Slater, Lucy Okell, Peter Gething, Azra Ghani, Maciej F Boni, Jonathan B. Parr, Jane Cunningham
medRxiv 2023.10.21.23297352; doi: <https://doi.org/10.1101/2023.10.21.23297352> Revision

[Projected health and economic effects of nonavalent versus bivalent human papillomavirus vaccination in the Netherlands: a data-driven analysis](#)

Birgit Sollie, Johannes Berkhof, Johannes A. Bogaards
medRxiv 2023.12.27.23300574; doi: <https://doi.org/10.1101/2023.12.27.23300574>

[Investigating the spatial accessibility and coverage of the pediatric COVID-19 vaccine: an ecologic study of regional health data](#)

Amin Bemanian, Jonathan F Mosser
medRxiv 2023.12.27.23300589; doi: <https://doi.org/10.1101/2023.12.27.23300589>

[Dengue Vaccine Effectiveness: Results from a Six-Year Population-Based Cohort Study in Southern Brazil](#)

Karin Regina Luhm, Silvia Emiko Shimakura, Sonia Mara Raboni, Magda Clara Vieira da Costa-Ribeiro, Fredi Alexander Diaz-Quijano, Angela Maron de Mello, Lineu Roberto da Silva, Marilene da Cruz Magalhães Buffon, Eliane Mara Cesário Pereira Maluf, Gabriel Graeff, Clara Preto, Gustavo Araújo de Almeida, Gabriela Amanda de Sousa, Elias Teixeira Krainski, Allan Arnold Evans, Denise Siqueira de Carvalho
medRxiv 2023.12.28.23300598; doi: <https://doi.org/10.1101/2023.12.28.23300598>

[The 8C model of vaccination readiness: A common framework to facilitate cross-study comparisons](#)

Piers Howe, Ferron Dearnley
medRxiv 2023.12.22.23300464; doi: <https://doi.org/10.1101/2023.12.22.23300464>

[COVID-19 pandemic re-shaped the global dispersal of seasonal influenza viruses](#)

Zhiyuan Chen, Joseph L.-H. Tsui, Bernardo Gutierrez, Simon Busch Moreno, Louis du Plessis, Xiaowei Deng, Jun Cai, Sumali Bajaj, Marc A. Suchard, Oliver G. Pybus, Philippe Lemey, Moritz U. G. Kraemer, Hongjie Yu
medRxiv 2023.12.20.23300299; doi: <https://doi.org/10.1101/2023.12.20.23300299>

[Maternal pertussis immunization and the blunting of routine vaccine effectiveness: A meta-analysis and modeling study](#)

Michael Briga, Elizabeth Goult, Tobias S Brett, Pejman Rohani, Matthieu Domenech de Cellès
medRxiv 2023.06.08.23291137; doi: <https://doi.org/10.1101/2023.06.08.23291137> Revision

[Quantifying the Risk of Conflict on Recent Ebola Outbreaks in Guinea and the Democratic Republic of the Congo](#)

Gina E C Charnley, Nathan Green, Ilan Kelman, Espoir B Malembaka, Katy A M Gaythorpe
medRxiv 2023.05.30.23290713; doi: <https://doi.org/10.1101/2023.05.30.23290713> Revision

[Rare disease gene association discovery from burden analysis of the 100,000 Genomes Project data](#)

Valentina Cipriani, Letizia Vestito, Emma F Magavern, Julius OB Jacobsen, Gavin Arno, Elijah R Behr, Katherine A Benson, Marta Bertoli, Detlef Bockenbauer, Michael R Bowl, Kate Burley, Li F Chan, Patrick Chinnery, Peter Conlon, Marcos Costa, Alice E Davidson, Sally J Dawson, Elhussein Elhassan, Sarah E Flanagan, Marta Futema, Daniel P Gale, Sonia García-Ruiz, Cecilia Gonzalez Corcia, Helen R Griffin, Sophie Hambleton, Amy R Hicks, Henry Houlden, Richard S Houlston, Sarah A Howles, Robert Kleta, Iris Lekkerkerker, Siying Lin, Petra Liskova, Hannah Mitchison, Heba Morsy, Andrew D Mumford, William G Newman, Ruxandra Neatu, Edel A O'Toole, Albert CM Ong, Alistair T Pagnamenta, Shamima Rahman, Neil Rajan, Peter N Robinson, Mina Ryten, Omid Sadeghi-Alavijeh, John A Sayer, Claire L Shovlin, Jenny C Taylor, Omri Teltsh, Ian Tomlinson, Arianna Tucci, Clare Turnbull, Albertien M van Eerde, James S Ware, Laura M Watts, Andrew R Webster, Sarah K Westbury, Sean L Zheng, Mark Caulfield, Damian Smedley
medRxiv 2023.12.20.23300294; doi: <https://doi.org/10.1101/2023.12.20.23300294>

[Assessing yellow fever outbreak potential and implications for vaccine strategy](#)

Keith Fraser, Arran Hamlet, Kévin Jean, Daniel Garkauskas Ramos, Alessandro Romano, Jennifer Horton, Laurence Cibrelus, Neil Ferguson, Katy Gaythorpe
medRxiv 2023.12.19.23300139; doi: <https://doi.org/10.1101/2023.12.19.23300139>

[The cascading impacts of attacks on health in Syria: A qualitative study of health system and community impacts](#)

Rohini J. Haar, Diana Rayes, Hannah Tappis, Leonard Rubenstein, Anas Rihawi, Mohamed Hamze, Naser Almhawish, Reham Wais, Hesham Alahmad, Ryan Burbach, Aula Abbara
medRxiv 2023.12.18.23300154; doi: <https://doi.org/10.1101/2023.12.18.23300154>

[Development and preliminary testing of Health Equity Across the AI Lifecycle \(HEAAL\): A framework for healthcare delivery organizations to mitigate the risk of AI solutions worsening health inequities](#)

Jee Young Kim, Alifia Hasan, Kate Kellogg, William Ratliff, Sara Murray, Harini Suresh, Alexandra Valladares, Keo Shaw, Danny Tobey, David E Vidal, Mark A Lifson, Manesh Patel, Inioluwa Deborah Raji, Michael Gao, William Knechtle, Linda Tang, Suresh Balu, Mark P Sendak
medRxiv 2023.10.16.23297076; doi: <https://doi.org/10.1101/2023.10.16.23297076> Revision

[Ethical dilemma arises from optimising interventions for epidemics in heterogeneous populations](#)

Pratyush K. Kollepara, Rebecca H. Chisholm, István Z. Kiss, Joel C. Miller
medRxiv 2023.02.18.23286135; doi: <https://doi.org/10.1101/2023.02.18.23286135> Revision

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>
[Provider Filter: OSF Pre-prints Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]

We observe increasing levels of "posting pollution" by individuals, sometimes posting 10+ items of no value. We will resume selective monitoring beginning in September.

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>
[Accessed 06 Jan 2024]

Selected Research

Study Protocol Open Access

[Experimental pneumococcal carriage in people living with HIV in Malawi: the first controlled human infection model in a key at-risk population](#) [version 1; peer review: awaiting peer review]

Klara Doherty, et al.

Abstract

Background: As well as suffering a high burden of pneumococcal disease people living with HIV (PLHIV) may contribute to community transmission in sub-Saharan African (sSA) settings. Pneumococcal vaccination is not currently offered to PLHIV in sSA but may prevent disease and reduce transmission. More evidence of vaccine effectiveness against carriage in PLHIV is needed. An Experimental Human Pneumococcal Carriage model (EHPC) has been safely and acceptably used in healthy adults in Malawi to evaluate pneumococcal vaccines against carriage and to identify immune correlates of protection from carriage. This study will establish the same model in PLHIV and will be the first controlled human infection model (CHIM) in this key population.

Systematic Review Open Access

[Ethics, equity, climate change, and infectious disease research: a scoping](#) review [version 1; peer review: awaiting peer review]

Hannah Markle, et al.

Abstract

Objectives

This scoping review aimed to summarise ethical issues related to climate-sensitive infectious diseases identified in the scientific literature.

Methods

We conducted a scoping review of PubMed to assess the level of engagement by scientists in the ethical and broader equity issues intersecting with climate-sensitive infectious diseases. Articles were included if they covered at least two out of three subjects – infectious disease, climate change, and ethics; and were published in English since 1995.

Results

The majority of scientific work in this field has focused on the relationship between climate change and vector-borne diseases (e.g., malaria and dengue fever) or water-borne diseases (e.g., cholera). Many studies identify the role of climate change in exacerbating inequities caused by the convergence of social and environmental determinants of health and show that the world's most vulnerable populations are disproportionately impacted. However, few studies included explicitly normative ethical analysis of these trends, and there was limited discussion of the ethical responsibilities arising in infectious disease research including in relationships between researchers and communities.

Conclusions

This review provides a foundation for renewed and ethically-informed research on climate-sensitive diseases in low-and middle-income countries. It also highlights critical knowledge gaps and reveals where more work is needed to understand and respond to the ethical implications of these relationships and thereby inform more ethically conscious infectious disease research.

*

*

*

*

[Think Tanks](#)

Brookings [to 06 Jan 2024]

<http://www.brookings.edu/>

Research

No new digest content identified.

Center for Global Development [to 06 Jan 2024]

<https://www.cgdev.org/>

All Research [Selected]

No new digest content identified.

Chatham House [to 06 Jan 2024]

<https://www.chathamhouse.org/>

Selected Analysis, Comment, Events

No new digest content identified.

Council on Foreign Relations [to 06 Jan 2024]

<https://www.cfr.org/media/news-releases>

New Releases [Selected]

No new digest content identified.

CSIS [to 06 Jan 2024]

<https://www.csis.org/>

Reports [Selected]

No new digest content identified.

Kaiser Family Foundation [to 06 Jan 2024]

https://www.kff.org/search/?post_type=press-release

Newsroom

No new digest content identified.

McKinsey Global Institute [to 06 Jan 2024]

<https://www.mckinsey.com/mgi/overview>

Latest Research

No new digest content identified.

ODI [Overseas Development Institute] [to 06 Jan 2024]

<https://odi.org/en/publications/>

Publications [Selected]

No new digest content identified.

Pew Research Center [to 06 Jan 2024]

<https://www.pewresearch.org/>

Latest Publications [Selected]

No new digest content identified.

Rand [to 06 Jan 2024]

<https://www.rand.org/pubs.html>

Published Research [Selected]

Tool

[RAND Methodological Guidance for Conducting and Critically Appraising Delphi Panels](#)

This manual provides methodological guidance and practical advice for what to consider when designing, implementing, and reporting Delphi panel results. It also includes a checklist that can be used to assess a Delphi study's quality.

Dec 29, 2023

Dmitry Khodyakov, Sean Grant, Jack Kroger, Melissa Bauman

Urban Institute [to 06 Jan 2024]

<https://www.urban.org/publications>

[New Research Publications - Selected](#)

World Economic Forum [to 06 Jan 2024]

<https://agenda.weforum.org/press/>

Media

No new digest content identified.

.....

.....

Public Consultations/Call for Inputs/Call for Papers

[Public consultation on antimicrobial manufacturing effluent guidance](#)

21 December 2023

Deadline: 26 January 2024.

Summary

WHO is seeking public feedback on draft "WHO Guidance on waste and wastewater management in pharmaceutical manufacturing with emphasis on antibiotic production"

Antibiotics provide great value to humanity to prevent and treat infectious disease. However, environmental emission of antibiotics during manufacturing has potential to contribute to the emergence and spread of AMR. Therefore, there is a recognised need, stemming from a World Health Assembly resolution and the [Global Action Plan on AMR](#), for international evidence-based guidance and tools on the management of manufacturing waste containing antimicrobials to guide the target audiences of this document.

Public submitters can download the draft guidance and background documents below and provide comments in the [online feedback form](#) before 26 January 2024.

:: [WHO Guidance on waste and wastewater management in pharmaceutical manufacturing with emphasis on antibiotic production](#)

:: [Background document on derivation of PNECs for resistance selection](#)

[Concept paper on the revision of the Non-clinical and Clinical Module of the influenza vaccines guideline \(PDF/177.49 KB\)](#)

EMA

First published: 31/10/2023 **Consultation dates: 01/11/2023 to 30/01/2024**

Summary/Problem statement [Excerpt]

The proposed guideline will replace Guideline on influenza vaccines, non-clinical and clinical modules (EMA/CHMP/VWP/457259/2014).

...The current guideline text addresses collection of vaccine effectiveness data for approved vaccines by season. The collection of reliable data, especially brand-specific data, has proven difficult even within countries with high quality influenza disease surveillance. There is a need to rediscuss the feasibility of the current recommendations, while still acknowledging the utility of such data to detect unexpected effectiveness signals.

Overall, there is some degree of urgency to revise the guideline on non-clinical and clinical development of influenza vaccines. In particular, to add sections relevant to the development of mRNA-based influenza vaccines and to reflect on how lessons learned from the COVID-19 pandemic could be relevant to the development of influenza vaccines, including those intended only for pandemic usage.

Comments should be provided using this [EUSurvey form](#). For any technical issues, please contact the [EUSurvey Support](#)

Call for Papers: Establishing the impact of WHO's normative and standard-setting functions: a call for papers

WHO - Bull World Health Organ. 2023 Oct 1; 101(10): 618–618A. Published online 2023 Oct 1.

The deadline for submissions is 1 March 2024

Editorial

Lisa M Askie^a, Rebekah AL Thomas^a, Rok Ho Kim^a, Mubashar Sheikh^a, Jeremy Farrar^b

doi: 10.2471/BLT.23.290829 PMID: PMC10523809

Normative leadership is a core function of the World Health Organization's (WHO) mandate, as outlined in its founding principles.¹ This leadership role is realized by developing evidence-based and ethically sound guidelines as well as other normative products that guide Member States in their public health decisions and actions, and by ensuring their recommendations are implemented.² WHO exercises its capacity for normative leadership to influence the development of legal norms and health policy and practice within its Member States...

... In the past five years, WHO has initiated a major change process, driven by its current Thirteenth Global Programme of Work,⁶ the transformation agenda, and the need to respond to major global events including the coronavirus disease 2019 (COVID-19) pandemic and other crises. More recently, WHO has developed a comprehensive strategy to enhance its capacities and capabilities at country level, to ensure that its normative work drives measurable impact for all people more effectively.

Despite these initiatives, to date it is unclear whether these changes have improved WHO's credibility and impact as a normative organization. Questions remain as to how successful WHO's normative leadership role has been, how it can be further strengthened and how the impact of WHO's work in countries should be measured and rated in the future. The recent COVID-19 pandemic exposed both the strengths of and the challenges to WHO's normative leadership and global reach. While realizing the crucial role of WHO as a key directing and coordinating authority, the global health community has also witnessed the unprecedented rise of misinformation and mistrust in science.

Considering the spotlight on WHO's global normative leadership role during the pandemic,⁷ and looking to prepare for future threats such as the health effects of climate change and ongoing conflict situations, the Bulletin of the World Health Organization calls for papers to help shape and inform WHO's mandate going forward. Topics of interest include: where has WHO succeeded in its normative leadership role? In what specific areas has it successfully shaped global health, and why were these initiatives successful? Where has WHO normative guidance been less impactful? If so, why was this the case, and what lessons can be learnt to improve impact in the future? What does the future of WHO's normative function look like, particularly in the context of digital technology and artificial intelligence? What aspects of the Organization's mandate, structure, function and administration need to be further strengthened or changed?

The Bulletin welcomes contributions from all stakeholders including public health decision-makers, researchers, and civil society and community representatives. Articles that propose innovative but feasible ways by which WHO can further strengthen its normative leadership and guidance role, are encouraged.

* * * * *
* * * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#); the [Bill & Melinda Gates Medical Research Institute](#), and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * * *
* * * * *